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Disabling the function of immune checkpoint molecules can unlock T cell immunity against cancer, yet
despite remarkable clinical success with monoclonal antibodies (mAb) that block PD-1 or CTLA-4 resistance
remains common and essentially unexplained. Certain tumors, especially pancreatic carcinoma, are fully
refractory to these antibodies. As reported in this thesis, I used a genetically engineered mouse model of
pancreatic carcinoma in which spontaneous immunity is minimal, and found that PD-L1 is prominent in the
tumor microenvironment, a phenotype confirmed in patients. Tumor infiltrating T cells express PD-1 even
more prominently than T cells in a classical model of chronic infection, in which anti-PD-1 mAb mediates
clinical benefit. Despite this striking expression of PD-1 and PD-L1 in the pancreatic tumor
microenvironment, treatment with anti-PD-1 mAb, with or without anti-CTLA-4 mAb, fails in well-
established tumors, recapitulating clinical results. Agonist anti-CD40 mAb with chemotherapy, deployed as a
vaccine, induces T cell immunity and reverses the complete resistance of pancreatic tumors to anti-PD-1 and
anti-CTLA-4. The combination of anti-CD40/chemotherapy plus anti-PD-1 and/or anti-CTLA-4 induces
regression of subcutaneous tumors, improves overall survival, and confers curative protection from multiple
rechallenges, consistent with immune memory not otherwise achievable. Combinatorial treatment nearly
doubles survival of mice with spontaneous pancreatic cancers, revealing a clinical opportunity. These findings
suggest that in non immunogenic tumors, epitomized by pancreatic carcinoma, baseline refractoriness to
checkpoint inhibitors may be rescued by the priming of a T cell response with an antitumor vaccine. These
studies indicate that understanding the immunobiology of differing tumor types may improve the ability to
rationally design combinatorial immunotherapies in oncology.
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ABSTRACT 
INDUCTION OF T CELL IMMUNITY OVERCOMES RESISTANCE TO PD-1 AND 
CTLA-4 BLOCKADE AND IMPROVES SURVIVAL IN PANCREATIC CANCER 
 
Rafael Winograd 
 
Robert H. Vonderheide 
 
Disabling the function of immune checkpoint molecules can unlock T cell immunity 
against cancer, yet despite remarkable clinical success with monoclonal antibodies (mAb) 
that block PD-1 or CTLA-4 resistance remains common and essentially unexplained. 
Certain tumors, especially pancreatic carcinoma, are fully refractory to these antibodies. 
As reported in this thesis, I used a genetically engineered mouse model of pancreatic 
carcinoma in which spontaneous immunity is minimal, and found that PD-L1 is 
prominent in the tumor microenvironment, a phenotype confirmed in patients. Tumor 
infiltrating T cells express PD-1 even more prominently than T cells in a classical model 
of chronic infection, in which αPD-1 mAb mediates clinical benefit. Despite this striking 
expression of PD-1 and PD-L1 in the pancreatic tumor microenvironment, treatment with 
αPD-1 mAb, with or without αCTLA-4 mAb, fails in well-established tumors, 
recapitulating clinical results. Agonist αCD40 mAb with chemotherapy, deployed as a 
vaccine, induces T cell immunity and reverses the complete resistance of pancreatic 
tumors to αPD-1 and αCTLA-4. The combination of αCD40/chemotherapy plus αPD-1 
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and/or αCTLA-4 induces regression of subcutaneous tumors, improves overall survival, 
and confers curative protection from multiple rechallenges, consistent with immune 
memory not otherwise achievable. Combinatorial treatment nearly doubles survival of 
mice with spontaneous pancreatic cancers, revealing a clinical opportunity. These 
findings suggest that in non immunogenic tumors, epitomized by pancreatic carcinoma, 
baseline refractoriness to checkpoint inhibitors may be rescued by the priming of a T cell 
response with an antitumor vaccine. These studies indicate that understanding the 
immunobiology of differing tumor types may improve the ability to rationally design 
combinatorial immunotherapies in oncology. 
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CHAPTER 1 – Introduction 
 
Cancer immune surveillance 
It has become evident that the microenvironment of solid malignancies are infiltrated by 
various populations of leukocytes which play roles in the promotion and regulation of 
tumor outgrowth (Hanahan and Weinberg, 2011). Postulation about the immune system’s 
role in cancer dates back more than a century to Paul Ehrlich’s hypothesis that the 
immune system holds malignancies at bay in long lived organisms (Ehrlich, 1909). This 
idea was revisited half a century later with the “immunological surveillance” hypothesis 
proposed by Sir Macfarlane Burnet and Lewis Thomas, arguing that control of early 
malignant lesions was an “evolutionary necessity” which could be orchestrated by the 
immune system (Burnet, 1957; Thomas, 1959; Burnet, 1970). Experimental verification 
of this hypothesis proved difficult until the development of inbred strains of mice that 
lacked key immune proteins (IFN-γ, perforin) or populations (Rag-2-/- mice without T, B, 
and natural killer T (NKT) cells) allowed for the unequivocal demonstration of immune 
control of tumor outgrowth (Shankaran et al., 2001; Street et al., 2001). The current 
principal hypothesis describing the immune system’s influence on tumor development 
was first posited by Robert Schreiber who proposed that “immunoediting” of nascent 
tumors occurs in three phases: elimination (of small immunogenic malignancies), 
equilibrium (between the nascent tumor and the immune system), and escape (of the 
tumor from immune surveillance through various immunosuppressive mechanisms) 
(Dunn et al., 2002). 
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 The immune system’s role in controlling and editing cancer is not an artifact of 
murine model systems. Immunosuppressed populations, whether from AIDS or 
immunosuppressive regimens following organ transplantation, are known to exhibit 
higher rates of malignancies (Vesely et al., 2011). Clinical evidence of immune responses 
to cancer were first suggested by studies correlating the presence of tumor infiltrating 
lymphocytes (TILs; specifically CD8+ T cells) with improved survival in patients with 
melanoma and ovarian and colorectal cancers (Clemente et al., 1996; Galon et al., 2006; 
Naito et al., 1998; Pagès et al., 2005; Zhang et al., 2003). More recently, the remarkable 
success of immune therapies in eliciting durable responses in cancer patients has laid the 
debate to rest, as combinatorial use of immune modulating antibodies and new targets are 
avidly being tested in preclinical and clinical studies (Brahmer et al., 2012; Hamid et al., 
2013; Hodi et al., 2010; Odorizzi and Wherry, 2012; Page et al., 2013; Topalian et al., 
2012). 
 The elimination phase of immunoediting hearkens back to the idea of tumor 
immune surveillance, in which somatic mutations that lead to malignant transformation 
and the accompanying disruption of normal tissue architecture allow for recognition of 
these cells by the immune system. Two of the “hallmarks of cancer” are the invasion of 
tissue and angiogenesis, processes which can lead to the production of proinflammatory 
molecules and the subsequent recruitment of innate immune cell populations such as NK 
cells and macrophages, among others (Dunn et al., 2004; Hanahan and Weinberg, 2011). 
Once these innate populations encounter tumor associated Natural killer group 2 member 
D (NKG2D) ligands, glycolipid-CD1d complexes, high-mobility-group box 1 (HMGB1), 
or other signals, their production of IFN-γ serves as a critical step in the mobilization of 
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the antitumor immune response, although various other cytokines and chemokines can 
augment this effect (Diefenbach et al., 2001; Dunn et al., 2002; Apetoh et al., 2007). 
Tumor cell death in the context of this inflammation allows for uptake of tumor antigens 
by the dendritic cells (DCs) and macrophages that have been recruited and activated by 
tumor associated cytokines; these antigen presenting cells (APCs) can then prime Th1 
CD4+ T cells, which in turn facilitate the cross-priming of CD8+ cytotoxic T lymphocytes 
(CTLs) by the APCs (Yu et al., 2003; Huang et al., 1994). Once primed, effector T cells 
can traffic to the tumor microenvironment and target tumor cells in an antigen specific, 
major histocompatibility complex (MHC) class-I dependent manner, serving as an 
extrinsic tumor suppressor mechanism (Schreiber et al., 2011). The elimination of 
malignant cells expressing tumor antigens can lead to the eradication of a lesion, but can 
also act to select for those tumor cells lacking the tumor antigen or expression of MHC 
class-I. 
 Rare malignant cells which avoid immune mediated elimination may enter into 
equilibrium with the immune system, in which outgrowth of tumors is prevented by the 
immune system but complete eradication is also not achieved. Evidence for equilibrium 
comes from experiments in which carcinogen induced tumors fail to grow in immune 
competent mice for months, but upon ablation of T cells or IFN-γ (but not innate immune 
components such as NK cells or NKG2D) half of the mice rapidly develop tumors at the 
site of carcinogen injection (Koebel et al., 2007). During the equilibrium phase tumors 
may gain the ability to avoid or suppress the immune processes holding it at bay, 
allowing for occult malignancies to escape immune suppression and grow into clinically 
apparent lesions.  
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The escape of tumors from immune control can be due to a variety of molecular 
and cellular mechanisms which occur in the context of high cancer mutation rates and the 
Darwinian-like selective pressure exerted by immune surveillance of these lesions. 
Tumor cell intrinsic mechanisms such as loss of antigen, antigen processing function, or 
MHC class-I have been shown to render these selected-for malignant cells all but 
invisible to immune pressure (Khong and Restifo, 2002). Resistance to apoptosis, 
achieved through the upregulation of antiapoptotic genes, for example, is a common 
feature of malignant cells and can also confer functional resistance to immune pressure 
(Hanahan and Weinberg, 2011).  
The establishment of an immunosuppressive microenvironment also allows for 
escape from immune surveillance. The secretion by tumor cells of immunosuppressive 
cytokines such as IL-10, transforming growth factor-β (TGF-β), and vascular endothelial 
growth factor (VEGF), among others, orchestrates the recruitment of regulatory immune 
and mesenchymal populations which in turn secrete factors which suppress effector 
immune functions and recruit further suppressive cells (Vesely et al., 2011). Various 
myeloid cell populations have been implicated in suppressing antitumor T cell immunity 
either directly or indirectly. Immature myeloid cells, also called myeloid derived 
suppressor cells (MDSCs), are increased in mice and humans with cancer, and can 
suppress T cell responses either directly by binding the inhibitory T cell immunoglobulin 
and mucin domain-containing protein 3 (TIM3) for example, or indirectly by locally 
depleting key T cell nutrients such as L-arginine and L-cysteine or through the secretion 
of reactive oxygen species (ROS) in the tumor microenvironment (Gabrilovich et al., 
2012). The polarization of tumor associated macrophages is also crucial to the 
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immunosuppressive microenvironment; tumor secreted factors promote the accumulation 
of macrophages with proangiogenic and tumor promoting properties. Unlike classical or 
‘M1’ macrophages, these ‘M2’ polarized cells do not secrete IL-12 (which can promote 
NK and T cell activation) but rather produce high levels of IL-10, which promotes the 
development of TH2 cells and the secretion of TGF-β and CCL22 which can drive 
regulatory T cell (Treg) development and recruitment, respectively (Gajewski et al., 
2013; Vesely et al., 2011). Tregs, in turn, inhibit effector T cell function through the 
consumption of IL-2 and through the inhibition of normal APC function by secretion of 
IL-10 and trans-endocytosis of the co-stimulatory molecules CD80/CD86 (Josefowicz et 
al., 2012; Qureshi et al., 2011). While every cancer type and especially every individual 
tumor are different, patterns have emerged as to the immunosuppressive mechanisms 
employed. Given the immense complexity and heterogeneity of malignancies, it is likely 
that the exact pattern and interplay of immune, mesenchymal and malignant components 
will never be completely understood, but tractable and druggable targets for therapeutic 
intervention have emerged and allow for the translation of basic biological findings into 
novel treatment for cancer patients. 
 
Negative immune checkpoints and cancer 
One of the most successful translations of cancer immunology into treatments is the 
recent demonstration that monoclonal antibodies blocking the programmed cell death 
protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) can 
improve survival in patients with melanoma and the subsequent FDA approval of these 
agents (Hamid et al., 2013; Hodi et al., 2010). Both PD-1 and CTLA-4 are cell surface 
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receptors expressed on T cells which are crucial to the normal regulation of the immune 
system and the prevention of rampant autoimmunity. The major role of PD-1  is to limit 
T cell activity in peripheral tissues during immune responses to pathogens by preventing 
the targeting of normal cells (Pardoll, 2012). Genetic loss of PD-1 in mice leads to the 
development of autoimmune cardiomyopathy and mortality, indicating the important role 
for this pathway in the prevention of autoimmunity (Nishimura et al., 2001). The main 
ligands for PD-1 are programmed death-ligand 1 (PD-L1) and programmed death-ligand 
2. PD-L1 is broadly expressed on many epithelial tissues, while both ligands can be 
expressed by various leukocyte subsets (Keir et al., 2008). Ligation of PD-1 on T cells 
leads to the recruitment of the Src homology 2 domain-containing tyrosine phosphatase 
(SHP-2), counteracting key kinases downstream of the T cell receptor (TCR) which drive 
T cell activation (Chemnitz et al., 2004; Freeman et al., 2000). PD-1 is transiently 
increased upon T cell activation and notably expressed at very high levels on exhausted 
CD4+ and CD8+ T cell populations (Blackburn et al., 2009; Crawford et al., 2014; 
Nishimura et al., 2001). CTLA-4 is a crucial immune checkpoint regulator expressed on 
T cells which out-competes CD28 for the ligation of CD80 and CD86. Unlike PD-1, 
which is thought to mediate its effect primarily at the effector stage, ligation of CTLA-4 
on effector cells inhibits the gene regulation effects immediately downstream of the 
CD28 costimulatory pathway, blunting the activation of the T cell (Parry et al., 2005). 
CTLA-4 can also downregulate T cell responses indirectly by the sequestration of CD80 
and CD86 from APCs through trans-endocytosis (Qureshi et al., 2011). CTLA-4 plays a 
crucial role in controlling autoimmune responses during normal biology as genetic loss of 
CTLA-4 leads to rampant lymphoproliferation, autoimmunity, and death in mice (Tivol 
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et al., 1995). Expression of CTLA-4 is found on effector T cells, but is most prominent 
on Tregs (its expression is partially driven by forkhead box P3 (FOXP3) the master 
transcriptional regulator of Tregs) where it enhances their immunosuppressive activity 
(Peggs et al., 2009; Wing et al., 2008). 
 The antibody mediated blockade of negative immune checkpoints to improve 
antitumor immunity was pioneered by the Allison group with the demonstration that an 
αCTLA-4 mAb led to antitumor immune responses in an immunogenic murine colon 
carcinoma model (Leach et al., 1996). Crucially, their experiments assuaged the fear that 
blockade of CTLA-4 would unleash rampant autoimmune toxicity as had been observed 
in mice genetically lacking CTLA-4 (Tivol et al., 1995). Further murine studies 
indicating the potential efficacy of targeting this pathway led to the development of 
clinical reagents and their testing in patients with advanced malignancies. The first report 
of tumor regressions in patients following treatment with an αCTLA-4 mAb (ipilimumab) 
was a study of patients with metastatic melanoma treated with both ipilimumab and a 
peptide vaccine against the gp-100 melanoma-associated antigen; two complete 
responses were reported, although 43% of patients experienced grade III/IV autoimmune 
toxicities, notably colitis and hypophysitis (αCTLA-4 mediated hypophysitis was later 
shown to be due to direct targeting of CTLA-4 expressed on cells in the pituitary gland 
(Iwama et al., 2014)) (Phan et al., 2003). In a phase III trial, treatment with ipilimumab 
led to a survival benefit in patients with metastatic melanoma, and importantly, 18% of 
patients were reported to survive long term (>2 years; compared to 5% in the other arm) 
despite being treated for only 3 months up front, indicating the potential for immune 
therapies to induce long lived antitumor memory responses (Hodi et al., 2010). When 
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added to the chemotherapeutic dacarbazine, ipilimumab significantly improved survival 
compared to dacarbazine alone; the results of these two studies led to FDA approval for 
ipilimumab (Robert et al., 2011). Recent work in murine models has led to an improved 
understanding of the mechanism of action of αCTLA-4 treatment; studies show that 
antitumor efficacy is due to both inhibition of negative signaling in effector cells as well 
as the depletion of Tregs, findings that are likely relevant to ipilimumab which is a 
human IgG1 mAb capable of mediating antibody-dependent cellular cytotoxicity 
(ADCC) and complement-dependent cytotoxicity (CDC) of bound target cells (Peggs et 
al., 2009; Simpson et al., 2013). Recent analysis of melanoma patients treated with 
αCTLA-4 has demonstrated that the treatment primarily acts to induce new antitumor 
CD8+ T cell responses rather than merely expanding those antitumor CD8+ T cells 
present prior to therapy, providing the first human in vivo evidence of this mechanism of 
action (Kvistborg et al., 2014). 
CTLA-4 is expressed systemically on T cells and this lack of tumor specificity led 
to early doubts about whether a therapeutic window existed for this target. While PD-L1 
is also systemically expressed, it has been found to be significantly overexpressed in the 
microenvironment of numerous solid tumors. Increased expression of PD-L1 has been 
demonstrated on myeloid populations in patients as well as on tumor cells themselves 
(Curiel et al., 2003; Dong et al., 2002; Duraiswamy et al., 2013). PD-L1 expression in 
tumors can be intrinsic, driven by oncogene activation such as EGFR in lung cancers or 
loss of the tumor suppressor PTEN in gliomas (Akbay et al., 2013; Parsa et al., 2006). 
Analyses of histologic sections of human melanoma and carcinomas of the lung, kidney, 
and head and neck has revealed a strong spatial correlation between the presence of TILs 
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and the expression of PD-L1 in these tumors (Lyford-Pike et al., 2013; Taube et al., 
2012; 2014; Velcheti et al., 2013). These data suggest that tumor cells upregulate PD-L1 
in response to immune pressure (specifically IFN-γ which is known to drive PD-L1 
expression in normal tissue) from infiltrating CD8+ T cells, a hypothesis termed ‘adaptive 
resistance’ (Keir et al., 2008; Sznol and Chen, 2013; Taube et al., 2012). Experimental 
evidence supporting this hypothesis was recently published in the B16 model of 
melanoma; using a genetic knockout and antibody depletion, tumor PD-L1 expression 
was shown to be dependent on both IFN-γ and CD8+ T cells (Spranger et al., 2013). 
Multiple mAbs blocking PD-1 and PD-L1 are in clinical development, and most 
have demonstrated comparable single agent clinical activity. Nivolumab is a fully human 
IgG4 αPD-1 mAb; in a large phase I study of multiple solid malignancies, objective 
responses were seen in 31%, 16%, and 29% of patients with metastatic melanoma, non-
small cell lung cancer (NSCLC), and renal cell carcinoma (RCC), respectively (Topalian 
et al., 2012). A competing αPD-1, pembrolizumab, recently received accelerated FDA 
approval for the treatment of melanoma after demonstrating an overall response rate 
(ORR) of 26% in a randomized expansion of a phase I trial (Hamid et al., 2013; Robert et 
al., 2014). The αPD-L1 MPDL3280A was recently shown to have a 26% ORR as a single 
agent in metastatic bladder cancer, and ORRs of 30%, 23%, and 14% in melanoma, 
NSCLC, and RCC, respectively (Herbst et al., 2014; Powles et al., 2014). Concurrent 
treatment with nivolumab and ipilimumab was recently found to lead to an ORR of 40% 
in patients with melanoma, which is better than the historical response rates of either 
agent alone, but was not compared to single agent treatment in this phase I study 
(Wolchok et al., 2013). 
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 Despite remarkable response rates in patients with some malignancies to single 
agent treatment with checkpoint inhibitors, other tumor types have demonstrated much 
less sensitivity to such intervention. Furthermore, even in ‘sensitive’ neoplasms most 
patients fail to respond to checkpoint inhibitor therapy; it is unclear whether the 
mechanisms of resistance for these two populations are similar or different. A few 
analyses of treated patient cohorts offer insights into in vivo mechanisms of action and 
predictors of response to antibodies blocking negative checkpoint molecules. Melanoma, 
for which the best response rates with single-agent checkpoint inhibition have been 
observed, segregates into distinct subpopulations based on the tumor immune 
microenvironment, and a pre-treatment immune gene signature was shown to predict 
response to ipilimumab in melanoma patients in a retrospective analysis (Gajewski et al., 
2010; Ji et al., 2011). These data suggest that αCTLA-4 acts to improve upon baseline 
immune responses to the tumor. However, a recent analysis of melanoma-specific CD8+ 
T cells in the peripheral blood of patients treated with ipilimumab found that although 
treatment significantly increased the number of detectable melanoma-specific CD8+ T 
cells responses, this was not due to an increase in the magnitude of pre-existing 
melanoma-specific CD8+ T cells (Kvistborg et al., 2014). Treatment with αCTLA-4 led 
to a broader repertoire of anti-melanoma CD8+ T cells but did not expand those 
melanoma-specific CD8+ T cells which were present prior to treatment (just as it did not 
expand virus specific CD8+ T cell responses). Taken together, these data suggest that 
αCTLA-4 may be facilitating the induction of novel antitumor T cell clones, but that this 
effect only has meaningful antitumor activity in patients in which a baseline antitumor 
immune response is already present. Whether this antitumor immune response allows for 
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better priming of antitumor T cells (i.e. through the availability of tumor antigen, 
presence of IFNs to facilitate proper T cell activation), or whether it facilitates trafficking 
and effector function of new antitumor T cells (localized secretion of chemokines or IL-
2) is unclear.  One study of patients treated with tremelimumab, another αCTLA-4 mAb, 
indicates that most patients (14/18) had increased TILs after treatment, but that this 
infiltrate does not correlate with response to treatment, further complicating the 
understanding of which metrics best predict response and resistance to αCTLA-4 
treatment (Huang et al., 2011). 
 Even less is understood about the mechanisms underlying sensitivity and 
resistance to αPD-1/αPD-L1 mAbs. Early hypotheses suggested that simply the presence 
of PD-L1 in the tumor microenvironment may predict responses, a finding that was true 
in a small cohort examined in a phase I study (Topalian et al., 2012). This same  
correlation did not hold true in a study of αPD-1 plus αCTLA-4 in melanoma patients, 
where objective responses were noted in 4/10 PD-L1 positive and 8/17 PD-L1 negative 
patients, however the concurrent treatment with αCTLA-4 confounds this data set 
(Wolchok et al., 2013). Two recent studies of patients treated with αPD-L1 indicated that 
pretreatment PD-L1 expression on tumor-infiltrating immune cells, but not on tumor 
cells, correlated with response in bladder cancer and NSCLC (Herbst et al., 2014; Powles 
et al., 2014). A complicating factor in these analyses is that PD-L1 expression correlates 
strongly with TILs in multiple malignancies; it is therefore difficult to determine whether 
responses to blockade of the PD-1/PD-L1 axis correlate with the presence of TILs or the 
expression of PD-L1 (Lyford-Pike et al., 2013; Taube et al., 2012; 2014; Tumeh et al., 
2014). The most recent analysis of melanoma patients treated with αPD-1 indicated that 
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the presence of CD8+ T cells, PD-1, and PD-L1 in pretreatment biopsies all strongly 
correlated with response (Tumeh et al., 2014). Histologic analyses have demonstrated 
that the tumor PD-L1 and TIL correlation is true beyond melanoma (specifically in head 
and neck squamous cell carcinoma (HNSCC), RCC, and NSCLC) and responses to αPD-
1/αPD-L1 have been observed in patients with lung and renal cancers (and one HNSCC 
patient (Herbst et al., 2014)), lending credence to the idea that a baseline antitumor 
immune response may predict the success of αPD-1 therapy (Brahmer et al., 2012; 
Lyford-Pike et al., 2013; Taube et al., 2014; Topalian et al., 2012; Tumeh et al., 2014). 
Specifically, the presence of a more clonal intratumoral CD8+ T cell population correlates 
with responses in melanoma patients treated with αPD-1, suggesting that unlike αCTLA-
4, targeting of the PD-1/PD-L1 axis works best on an already present antigen specific 
antitumor CD8+ T cell population, rather than simply an inflammatory tumor 
microenvironment (TME) (Tumeh et al., 2014; Kvistborg et al., 2014).  
Recent work in murine models supports the notion that checkpoint blockade acts 
on an existing immune response. The augmentation of antitumor T cell responses with 
vaccines, peritumoral poly(I:C), or intratumoral oncolytic virus has been shown to 
improve baseline responses to checkpoint inhibitors in murine models of melanoma, 
ovarian cancer, and colon cancer (Bald et al., 2014; Duraiswamy et al., 2013; Zamarin et 
al., 2014; Zhou et al., 2010). Additionally, a recent study by Dr. Schreiber and colleagues 
indicates that in a murine sarcoma model αPD-1 or αCTLA-4 act to induce expansion and 
activation of tumor antigen-specific CD8+ T cells (Gubin et al., 2014). Taken together, 
the preclinical and clinical data suggest that responses to αPD-1/αPD-L1 and αCTLA-4 
depend on a preexisting antitumor immune responses, that αCTLA-4, specifically, 
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induces novel tumor-specific CD8 T cells, and that therapeutic induction of antitumor T 
cells can augment the percentage of responders in tumor systems with baseline sensitivity 
to checkpoint inhibitors. However, some tumor types, such as pancreatic ductal 
adenocarcinoma (PDA), are fully refractory to checkpoint inhibitors in clinical studies 
(Brahmer et al., 2012; Le et al., 2013; Royal et al., 2010). It is unclear to date whether 
any therapeutic approaches can extend the range of checkpoint inhibitor therapy to those 
tumor types that are resistant. 
 
Pancreatic ductal adenocarcinoma and the KPC model 
PDA is a lethal, aggressive, and common disease with the lowest 5-year patient survival 
rate of any tumor type routinely tracked (6%) (Howlander et al., 2013). Currently PDA 
ranks fourth in cancer deaths per year, but the incidence of PDA is rising, fueled by an 
aging population and the increasing prevalence of obesity and diabetes, and it is 
calculated to become the second leading cause of cancer death in the United States by 
2020 (Hidalgo, 2010; Rahib et al., 2014). Although the causes of pancreatic cancer are 
unknown, several factors have been shown to increase risk; tobacco use increases risk the 
most (2.5-3.6 fold) while obesity, diabetes, and alcohol use also confer increased risk 
(Hidalgo, 2010). Several factors contribute to the high death rate in patients with PDA; 
the retroperitoneal location of the pancreas allows for the tumors to develop relatively 
unnoticed, causing nonspecific symptoms such as back pain and fatigue so that the vast 
majority (~80%) of patients have advanced disease upon diagnosis, precluding surgical 
resection (Hidalgo, 2010). Pancreatic cancer is also remarkably resistant to most 
therapeutic interventions; despite recent approval of two new chemotherapeutic regimens 
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(FOLFIRINOX and gemcitabine + nab-paclitaxel), patient response rates remain low 
(31.6% and 23%, respectively) and durability of responses is tragically short (Conroy et 
al., 2011; Von Hoff et al., 2013). Furthermore, both regimens, but especially 
FOLFIRINOX, can be difficult for patients to tolerate. 
PDA develops progressively from precursor lesions termed pancreatic 
intraepithelial neoplasia (PanIN) which have been divided into stages based on histologic 
analysis of their epithelial polarity and nuclear aberrations into PanIN-1a, PanIN-1b, 
PanIN-2, and PanIN-3 (carcinoma in situ) (Rustgi, 2006). Each progressive stage is 
associated with greater frequency of mutations in prototypical oncogenes and tumor 
suppressors. Other pancreatic lesions such as mucinous cystic neoplasia and intraductal 
papillary mucinous neoplasia have also been identified as precursor lesions for PDA 
(Kopp et al., 2012). Strikingly, over 90% of pancreatic ductal tumors bear an activating 
mutation in the KRAS2 oncogene; this mutation locks this key GTP-ase in its active form, 
leading to constitutive signaling down the PI3K and MEK/ERK pathways, among others 
(Hidalgo, 2010; Rustgi, 2006). The high frequency of this mutation, and the importance 
of these signaling pathways in driving cell proliferation and survival, have led to a 
general consensus that Kras is the driving mutation in PDA, a theory confirmed when 
induction of KrasG12D (constitutively active) in the pancreata of mice led to progressive 
development of PanIN lesions and PDA (Hingorani et al., 2003). Interestingly, despite 
the ductal appearance of PDA lesions, recent work in mice has demonstrated that the 
induction of oncogenic Kras leads to more PanINs when induced in acinar cells (through 
the promoter Ptf1a) compared to ductal/centroacinar cells (Sox9 promoter), suggesting 
that acinar cells may be the cell of origin for most pancreatic tumors (Kopp et al., 2012). 
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The transcription factor Prxx1, transiently induced with pancreatitis or pancreatic injury, 
upregulates Sox9 and contributes to acinar-to-ductal metaplasia, a key feature of the 
transformation of acinar cells to PDA upon KrasG12D expression, pancreatitis, or both 
(Kopp et al., 2012; Reichert et al., 2013). Other than Kras, inactivation of the tumor 
suppressors TP53 and CDKN2A (p16Ink4A) is very common in PDA (50%-75% and 90%-
95%, respectively) and each of these has been shown to cooperate with KrasG12D to 
induce PDA in genetic mouse models (Aguirre et al., 2003; Hingorani et al., 2005). 
The genetically engineered PDA model that we used in our studies is the KPC 
model in which KrasG12D and TP53R172H (a dominant-negative isoform analogous to the 
cancer predisposing mutation found in the Li-Fraumeni syndrome) are targeted to the 
endogenous loci and rendered quiescent by floxed transcriptional and translational 
silencing cassettes expressed in the promoter. Pancreas specific Cre recombinase, driven 
by the Pdx-1 promoter, excises the silencing cassettes leading to expression of KrasG12D 
and TP53R172H in all cells of the pancreatic lineage (Hingorani et al., 2005). These KPC 
mice stochastically develop pancreatic adenocarcinoma with 100% penetrance within the 
first 6 months of life. The KPC model recapitulates the molecular, histopathologic, and 
clinical features of human pancreatic adenocarcinoma, including the progression through 
PanIN lesions and metastasis to peritoneum, liver and lung (Beatty et al., 2011; Clark et 
al., 2008; Hingorani et al., 2005). 
Histologically, PDA is distinguished by a dense desmoplastic stroma, rich in 
fibroblasts, extracellular matrix (ECM), and inflammatory leukocytes. The cellular 
populations in the stroma play many roles in pancreatic cancer development, progression, 
invasion, and immune evasion, and the non-cellular components, including collagen, 
16 
fibronectin and hyaluronic acid, contribute to the elevated intratumoral hydrostatic 
pressure thought to cause poor drug delivery (Provenzano et al., 2012; Shepard et al., 
2012). Reprogramming of pancreatic fibroblasts during tumorigenesis is a key pathway in 
the induction of pathologic fibrosis and the fibroblasts in human PDA upregulate genetic 
programs involved in ECM deposition, inflammation, and growth factor secretion 
(Sherman et al., 2014). 
Since the stromal compartment has not undergone malignant transformation it 
may be more susceptible to intervention. Therapeutic ablation of hyaluronic acid 
decreases intratumoral hydrostatic pressure, increases intratumoral drug levels, and can 
synergize with gemcitabine to enhance survival in preclinical studies of a genetic mouse 
model of PDA, prompting a currently ongoing clinical study (Provenzano et al., 2012) 
(NCT01839487). Another approach to targeting PDA stroma is through inhibition of the 
paracrine signaling of the hedgehog pathway. Secretion of hedgehog ligands by PDA 
cells leads to increased activation of stromal cells, and pharmacologic inhibition of the 
Smoothened receptor in KPC mice decreases the desmoplastic stroma and improves 
survival when combined with gemcitabine (Olive et al., 2009). However, unlike the 
promising interim data of the hyaluronidase trial, a clinical study of Smoothened inhibitor 
with gemcitabine in PDA patients was halted when interim analysis showed that patients 
receiving the Smoothened inhibitor fared worse than those treated with gemcitabine 
alone, raising questions as to the role of the tumor stroma in PDA (Amakye et al., 2013). 
Recent work demonstrates that stromal ablation in KPC mice, either through genetic 
depletion of αSmooth muscle actin+ (αSMA) myofibroblasts or through deletion of Sonic 
hedgehog (Shh) in tumor cells, leads to the development of poorly differentiated 
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pancreatic tumors and accelerated death compared to control KPCs (Rhim et al., 2014; 
Özdemir et al., 2014). These studies indicate that tumor stroma in PDA may in fact be 
protective;  this is potentially part of a wound-healing response gone awry, a mechanism 
thought to be involved in solid tumorigenesis (Hanahan and Weinberg, 2011). PDA 
desmoplasia may slow the outgrowth of undifferentiated tumors, but several groups 
demonstrate that depletion of the stroma, or the fibroblasts responsible for generating the 
stromal response, in fact potentiates other therapeutic modalities. The Stanger group 
demonstrated that in KPC mice lacking Shh, an αVEGFR2 mAb prolonged survival, 
while it did not in Shh sufficient KPCs; also, the depletion of fibroblast activating 
protein+ (FAP) or αSMA+ fibroblasts potentiates checkpoint inhibitor mediated antitumor 
effects in two studies of KPC mice (Feig et al., 2013; Rhim et al., 2014; Özdemir et al., 
2014). Lastly, the vitamin D analogue calcipotriol was recently shown to bind the vitamin 
D receptor on pancreatic fibroblast and induce a reversion of their pro-tumorigenic gene 
signature, leading to fibroblasts resembling quiescent pancreatic stellate cells (Sherman et 
al., 2014). The use of calcipotriol (in combination with gemcitabine) in KPC mice led to 
decreased collagen and increased vasculature in pancreatic tumors, and was able to 
prolong survival compared to gemcitabine alone (Sherman et al., 2014).  
While some of these data may seem contradictory, some general conclusions can 
be made about fibroblasts and ECM in PDA. During pancreatic tumorigenesis signals 
from tumor cells (such as Shh ligands) and local inflammation can induce quiescent 
pancreatic fibroblasts to become activated; these fibroblasts upregulate αSMA and 
undergo genetic reprogramming, likely programs that are part of normal wound healing 
responses. However, in these cancer associated fibroblasts the activated genetic program 
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is maintained, as the ‘wound’ does not heal, and their secretion of ECM, proinflammatory 
signals, and growth factors becomes pathologic and contributes to the formation of the 
dense fibrotic stroma associated with PDA. This response may actually slow the 
outgrowth of pancreatic tumor cells, but also has immunosuppressive effects and prevents 
successful drug delivery to tumor cells. For therapeutic purposes, ablation of the stromal 
compartment may potentiate other therapeutic approaches, but must be approached with 
caution given the potential to accelerate tumor growth. 
Immunologically, the pancreatic tumor microenvironment is notable for a robust 
leukocytic infiltrate, one recapitulated in the KPC model (Beatty et al., 2011; Clark et al., 
2008; 2007). Both human and murine PDA conspicuously lack a notable CD8+ T cell 
infiltrate; rather, many of the TILs in PDA are Tregs (Bernstorff et al., 2001; De Monte et 
al., 2011; Fukunaga et al., 2004; Hiraoka et al., 2006; Clark et al., 2007; Zhang et al., 
2014). In the KPC model, Tregs are present as early as the PanIN stage, and other 
immunosuppressive populations such as tumor associated macrophages (TAMs) and 
MDSCs are also increased in the pancreata of KPC mice harboring PanIN lesions (Clark 
et al., 2007). In pancreatic tumors, TAMs and MDSCs each make up, on average, 10% of 
the cellular composition of these tumors, highlighting the prominent role these 
suppressive myeloid populations occupy in PDA (Clark et al., 2007). 
The immunosuppressive role of TAMs and MDSCs in this model of PDA has 
been well characterized. MDSC proliferation in KPC mice is driven by tumor derived 
granulocyte-macrophage colony-stimulating factor (GM-CSF), secretion of which is 
driven by oncogenic KrasG12D (Bayne et al., 2012; Pylayeva-Gupta et al., 2012). GM-
CSF drives extramedullary hematopoiesis in the spleens of KPC mice, and MDSCs 
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accumulate systemically and are recruited to the tumor and metastases (Bayne et al., 
2012). These immature myeloid cells suppress CD8+ T cell responses; they exhibit high 
levels of arginase and inducible nitric oxide synthase (iNOS) activity, both known 
mechanisms of MDSC suppression (Bayne et al., 2012; Gabrilovich et al., 2012).  
Recently, Dr. Vonderheide and I collaborated with the Gabrilovich group to show 
that KPC MDSCs express increased Trailr2, a death receptor which is upregulated in 
MDSCs upon ER stress, and which is responsible for increased MDSC turnover in tumor 
bearing hosts, stimulating the proliferation of MDSC precursors in a feed-forward 
mechanism (Condamine et al., 2014). Importantly, in an implantable tumor model the 
overexpression of Trailr2 allowed for selective depletion of MDSCs (leaving normal 
monocytes and neutrophils unaffected) in tumor bearing hosts, potentiating an antitumor 
T cell response (Condamine et al., 2014). TAMs in the KPC model also have 
immunosuppressive propreties, secreting IL-10 and IL-6 and expressing little MHC class 
II; treatment with an agonist αCD40 can transiently reprogram these macrophages and 
induce upregulation of MHC class II and the costimulatory molecule CD86, and imbue 
them with tumoricidal properties in vitro (Beatty et al., 2011). Treatment of KPC mice 
with αCD40 leads to an increase in systemic IL-12, TNF-α, and IFN-γ and causes 
macrophage-dependent tumor regression with a notable involution in the tumor stroma; a 
clinical study of αCD40 (with gemcitabine) treatment of PDA patients also led to partial 
responses in 4/21 patients (Beatty et al., 2011; 2013). Depletion of TAMs in an 
orthotopic model, using KPC or KrasG12D p16Ink4A derived cell lines, by inhibition of 
colony-stimulating factor 1 receptor (CSF1R; a chemokine receptor important for 
macrophage trafficking into tissues) also reversed their immunosuppressive effects and 
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allowed for improved CD8+ T cell responses against the orthotopic tumors (Zhu et al., 
2014). 
The prevalence of populations of Tregs, TAMs, MDSCs, and fibroblasts in PDA 
tumors lends credence to the notion that the PDA TME is particularly 
immunosuppressive, but increasingly, there is an appreciation from studies in KPC and 
other PDA models of an underlying sensitivity of PDA tumor cells to T cell cytotoxicity 
(Vonderheide and Bayne, 2013). The dearth of effector T cells at all stages of 
tumorigenesis, combined with the appearance of immunosuppressive populations as early 
as the PanIN stages  suggest that PDA tumors may be functionally immune privileged 
sites. Nevertheless, the lack of PDA immunogenicity does not necessarily indicate an 
inherent lack of antigenicity of PDA tumor cells; indeed, to the extent that effector T cells 
minimally encounter PDA tumor cells during the entire natural history of this cancer, 
PDA cells might be unexpectedly sensitive to T cell killing because they have not been 
exposed to Darwinian-like T cell selective pressure in vivo. Without T cell pressure, T 
cell escape and classical immunoediting may not be necessary for pancreatic tumor 
growth as it is for highly immunogenic tumors (Schreiber et al., 2011; Vonderheide and 
Bayne, 2013). This may explain the ability to induce T cell responses against pancreatic 
cancers when suppressive populations are deleted or inhibited (Bayne et al., 2012; Feig et 
al., 2013; Zhu et al., 2014; Özdemir et al., 2014). 
 
Goals and key findings of this thesis project 
While checkpoint blockade has produced remarkable single agent results in patients with 
melanoma, lung cancer, and kidney cancer, most patients fail to respond. Furthermore, 
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certain tumors, notably pancreatic cancer, are fully refractory to these agents to date. In 
the studies reported here, I tested the hypothesis that failed immune recognition or poor T 
cell priming underlies weak clinical responses to checkpoint therapy, i.e. induction of T 
cell immunity is required to potentiate tumor regressions not otherwise achievable with 
checkpoint blockade alone in minimally immunogenic tumors such as PDA. I used the 
KPC mouse model of spontaneous PDA which recapitulates the molecular, histologic, 
and immune parameters of the human disease and has predicted clinical responses (Bayne 
et al., 2012; Beatty et al., 2011; Clark et al., 2007;  Hingorani et al., 2005; Provenzano et 
al., 2012; Sherman et al., 2014). Both the KPC and KPC derived subcutaneous tumor 
models were used to assess the relevance of the PD-1/PD-L1 and CTLA-4 pathways in 
pancreatic cancer, and to assess tumor responses to mAbs that block these key negative 
immune checkpoints. Analysis of human PDA tumors was performed to confirm the 
clinical relevance of our findings in the murine models. I induced T cell immunity using 
an agonistic αCD40 in combination with chemotherapy (Elgueta et al., 2009; Nowak et 
al., 2003), and compared the impact and mechanism of αPD-1/αCTLA4 mAb with or 
without this vaccine, examining only well-established tumors. Thus the main goal of this 
project was to model the clinical resistance of pancreatic cancer to checkpoint inhibitor 
therapy and to determine whether the induction of a T cell response could overcome this 
resistance and lead to immune mediated regression and rejection of PDA. 
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CHAPTER 2 – Materials and Methods 
*Most of the methods in this chapter have been described in manuscripts:  
Winograd et al., Beatty et al. (see page v for full citations) 
 
Mice 
All animal protocols were reviewed and approved by the Institutional Animal Care and 
Use Committee of the University of Pennsylvania. KrasLSL-G12D/+, Trp53LSL-R172H/+, Pdx1-
Cre (KPC) mice (Hingorani et al., 2005), and their littermates Trp53LSL-R172H/+, Pdx1-Cre 
(PC) mice were used for studies in Chapter 4. KPC mice and KrasLSL-G12D/+,  
Trp53LSL-R172H/+, Pdx1-Cre, LSL-Rosa-YFP (KPC-Y) (Rhim et al., 2012) were 
backcrossed 10 generations on the C57BL/6 background for studies in Chapter 3. Six- to 
eight-week-old female C57BL/6 and B6.129S7-Ifngtm1Ts/J (IFN-γ ko) mice used for 
implantable tumor studies were from Jackson Laboratories. 
 
Patient Samples and Analysis 
Formalin-fixed, paraffin-embedded tissue samples were prepared after surgical resection 
of patients with resectable pancreatic carcinoma according to an IRB-approved protocol. 
Immunohistochemistry was performed using antibodies against CD8 (Clone C8/144B; 
Dako M7103; 1:40) and PD-L1 (Clone E1L3N; Cell Signaling 13684; 1:75).  Staining 
was performed on a Leica BondTM instrument using the Bond Polymer Refine Detection 
System (Leica AR9800).   Heat-induced epitope retrieval was done for 20 minutes in 
either ER1 solution (Leica AR9961) for CD8 or ER2 solution (Leica AR9640) for PD-
L1.  PD-L1 staining required extended incubation for primary antibody (1 hour) and 
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polymer (20 minutes). Sections were analyzed by a senior pancreatic cancer clinical 
pathologist. All slides were scanned using the Aperio System. Utilizing the virtual slides, 
three fields within and outside the tumor bed were randomly selected for each case; care 
was taken to exclude fields encompassing lymphoid aggregates (follicles).  For each 
field, the area was calculated by the imaging system and the number of CD8+ cells was 
counted manually. For each field, the number of positive cells per area was calculated 
and the average of the three fields was calculated for each case to normalize for differing 
size fields, thereby eliminating any size field counting bias.  PD-L1 staining (both 
membranous and cytoplasmic) was scored as 1+ (minimal expression), 2+ (moderate 
expression), 3+ (high expression), or 4+ (intense expression). 
  
Collection of Tissue Samples from Mice 
The entire pancreas (KPC) or subcutaneous tumor was washed in PBS, minced into small 
fragments, and incubated in collagenase solution (1 mg/ml collagenase V in DMEM) at 
37°C for 45 min. Dissociated cells were passed through a 70 μM cell strainer twice and 
washed three times in DMEM. Spleens and lymph nodes were homogenized and passed 
through a 70 μM cell strainer to achieve single cell suspensions. For spleens, red blood 
cells were lysed using ACK Lysis Buffer (BioWhittaker). 
 
Cell Lines 
PDA cell lines from KPC (backcrossed or not) or KPC-Y mice were derived from single 
cell suspensions of PDA tissue, as previously described (Beatty et al., 2011). Dissociated 
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cells were plated in a 6-well dish with serum free DMEM. After 2 weeks, media was 
changed to DMEM + 10% FCS. After 4-10 passages, cells were used in experiments.  
 
In vivo Mouse Studies 
For implantable tumor experiments, PDA tumor cells (5x105 for studies in Chapter 3; 
1x106 for studies in Chapter 4) were injected subcutaneously in PBS onto the flanks of 
mice and allowed to grow 9-12 days until tumor volumes averaged 30-100mm3. Mice 
were then enrolled into treatment groups such that cohorts were balanced for baseline 
tumor size. Mice were treated intraperitoneally (i.p.) with αPD-1 (RMP1-14, BioXcell; 
200μg per dose) on days 0, 3, 6, 9, 12, 15, 18, and 21 (after enrollment) and/or αCTLA-4 
(9H10, BioXcell; 200μg per dose) on days 0, 3, and 6. All antibodies were endotoxin 
free. Clinical grade gemcitabine (Eli Lilly) was purchased through the Hospital of the 
University of Pennsylvania Pharmacy; clinical grade nab-paclitaxel was either purchased 
or a kind gift from Celgene. Chemotherapy vials were resuspended and diluted in sterile 
PBS, and injected i.p. at 120 mg/kg (for each chemotherapeutic) on day 1. As a control 
for the human albumin component of nab-paclitaxel, control cohorts were treated with 
human albumin at the same dose as the albumin component of nab-paclitaxel (108 
mg/kg) on day 1 (Sigma Life Science). Agonistic αCD40 (FGK45, BioXcell; 100μg) was 
given i.p. on day 3. For T cell depletion studies, αCD8 (2.43, BioXcell; 200μg per dose) 
and αCD4 mAbs (GK1.5, BioXcell; 200μg per dose) were injected i.p. twice weekly for 
the duration of the experiment, starting on day 0 (day of enrollment). For isotype 
controls, rat IgG2a (2A3, BioXcell; 100μg) and rat IgG2b (LTF-2, BioXcell; 200μg per 
dose) were used i.p.. This approach achieved >98% depletion of CD8+ and CD4+ T cells 
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in peripheral blood and tumor tissue compared to control mice, as monitored by flow 
cytometry. For tumor rechallenge studies, αCD8 or isotype control antibodies were 
injected i.p. the day before the second rechallenge and continued twice weekly until day 
60 or until the mouse was sacrificed for tumor burden. To monitor growth of 
subcutaneous tumors, tumor diameters were measured by calipers and volume calculated 
by 0.5 x L x W2 in which L is the longest diameter and W is the perpendicular diameter. 
Endpoint criteria for the survival studies included tumor volume exceeding 1,000 mm3 or 
tumor ulceration. Mice that died suddenly or developed vestibular signs, as described in 
Figure 30, with minimal tumor burden were censored on the day of death or euthanasia. 
For studies using the KPC model, young KPC mice were monitored by abdominal 
palpation and/or ultrasonography as previously described (Beatty et al., 2011) (Vevo 
2100 Imaging System with 55MHz MicroScan transducer, Visual Sonics) for the 
development of pancreatic tumors. Mice with ultrasound diagnosed tumors of volume 30-
150 mm3 were enrolled and block randomized into treatment groups. Tumors were 
visualized and reconstructed for quantifying tumor volume using the integrated Vevo 
Workstation software package. Baseline tumor volume was not significantly different 
across cohorts. KPC mice were treated with the same dose and schedule of antibodies and 
chemotherapeutics as noted above in the subcutaneous model. Mice were censored from 
study if they developed a secondary malignancy (n=1). Endpoint criteria included tumor 
volume exceeding 1,000 mm3 (by ultrasonography), severe cachexia, or extreme 
weakness and inactivity.  
 For explanted tumor studies, tumors from non-backcrossed KPC mice were 
dissected and 3x3 mm tumor chunks were implanted subcutaneously in PC mice. In the 
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“two tumor” models, explanted pancreatic tumor chunks or a PDA cell line (as described 
above) were injected subcutaneously in non-backcrossed KPC mice bearing ultrasound 
diagnosed tumors. Mice were treated starting on day 12-13 as further described in Figures 
33 and 36. 
 
Antibodies 
The following monoclonal antibodies were used for flow cytometry: from BD 
Biosciences, αCD45 (30-F11; V500), αCD3 (145-2C11; PerCP, APC-Cy7), αCD19 
(1D3; APC, V450), αCD8 (53-6.7; APC-Cy7, PerCP-Cy5.5), αCD11c (HL3; V450, 
APC), αCD4 (RM4-5; V450, PerCP-Cy5.5), αFoxP3 (FJK-16S; APC), αCD31 
(MEC13.3; PE, FITC, APC); αH-2Kb (MHC class I) (AF6-88.5; PE); from eBiosciences, 
αF4/80 (BM8; FITC, PerCP, PE-Cy7), αCD45(30-F11; eFluor605), αFoxP3 (FJK-16S; 
PE), αLag-3 (C9B7W; APC), αB220 (RA3-6B2; APC-eFluor780), αNK1.1 (PK136; 
APC-eF780); and from Biolegend, αCD274 (PD-L1) (10F.9G2; PE), αCD279 (PD-1) 
(29F.1A12; FITC; RMP1-30; PE-Cy7), αCD90.2 (53-2.1; PerCP), αLag-3 (C9B7W; 
PerCP-Cy5.5), αCD8 (53-6.7;PE-e610), αKi-67 (16A8; FITC). Viability was assessed 
using either 7-aminoactinomycin D (7-AAD; BD Biosciences) or Live/Dead Fixable 
Aqua Dead Cell Stain Kit (Life Technologies). 
 
Flow Cytometry 
Single cell suspensions were stained with fluorochrome-labeled antibodies at 4°C for 
15 min in PBS/1% FCS/2mM EDTA. Intracellular staining was done using a 
fixation/permeabilization kit (eBioscience). Cells were acquired on a FACSCanto or LSR 
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II flow cytometer (BD Biosciences) and were analyzed using BD FACSDiva software 
(BD Biosciences) or FlowJo (TreeStar). 
 
In vitro IFN-γ stimulation of tumor cells 
KPC-derived PDA cell lines were plated, allowed to rest overnight, and had media 
replaced the next day with complete media containing IFN-γ (R&D Systems) at 50 
ng/mL. Cells were cultured with or without IFN- γ for 24 or 48 hours and then collected 
for flow cytometric analysis. 
 
Immunohistochemistry 
For analysis of CD3 (AbD Serotec, KT3, 1:100), CD4 (BioXCell, GK1.5, 15 μg/mL), 
CD8 (BioXcell, 2.43, 15 μg/mL), and Foxp3 (EBioscience, FJK-16s, 1:40), frozen 
sections fixed in 100% methanol were analyzed as previously described (Bayne et al., 
2012). For quantification, the number of cells was counted per 40x field with a minimum 
of 4 fields per tumor quantified. 
 
LCMV Clone 13 infection 
Lymphocytic choriomeningitis virus (LCMV) clone 13 was propagated, titered and used 
as previously described (Blackburn et al., 2009). C57BL/6 mice were infected 
intravenously with 4x106 PFU of LCMV clone 13. Mice were sacrificed on day 30 post 
infection and tissues harvested for analyses. 
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Statistical Analysis 
Differences between two groups were analyzed by two-tailed Student’s T test. 
Differences between three or more groups were analyzed by one-way ANOVA with 
Bonferonni’s multiple comparison test used as a post hoc test to assess differences 
between any two groups. Tumor growth curves were analyzed by two-way ANOVA, 
with Tukey multiple comparisons of means used as a post hoc test to assess differences 
between any two groups. Survival curves were assessed by Log-rank (Mantel-Cox). 
Correlation between two groups was assessed by Spearman’s Rank Correlation 
Coefficient. Significance of tumor regressions on ‘waterfall plots’ was determined using 
Fisher's Exact test. All statistical analyses were performed on GraphPad Prism 6 
(GraphPad), except 2-way ANOVA and related post hoc testing, which were performed 
on R Statistical Software (R Core Team). p≤0.05 was taken as significant. 
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CHAPTER 3 – Induction of T cell immunity with chemotherapy and agonist αCD40 
overcomes resistance to checkpoint inhibitors in pancreatic cancer 
 
*The majority of the results described in this chapter are in a manuscript currently 
undergoing revisions at Cancer Immunology Research: Winograd, R., Byrne, K.T., 
Evans, R.A., Odorizzi, P.M., Meyer, A.R.L., Bajor, D.L., Clendenin, C., Stanger, B.Z., 
Furth, E.E., Wherry, E.J., and Vonderheide, R.H. Induction of T cell immunity 
overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in 
pancreatic carcinoma 
 
INTRODUCTION 
It is now well-appreciated that T cells are key mediators of antitumor immunity and 
regulate the outcome of tumor immune surveillance (Schreiber et al., 2011). Critical to 
this regulation are lymphocyte inhibitory receptors such as PD-1 and CTLA-4 which 
restrain T cell antitumor immunity (Odorizzi and Wherry, 2012; Page et al., 2013; 
Pardoll, 2012; Sznol and Chen, 2013). Monoclonal antibodies that block the interaction 
of PD-1 or CTLA-4 with their ligands induce T-cell dependent tumor regression in many 
experimental systems (Page et al., 2013; Pardoll, 2012). In the clinic, unprecedented rates 
of tumor regressions have been observed in patients with melanoma and carcinomas of 
the lung and kidney following treatment with mAb against CTLA-4, PD-1, or PD-L1 
(Brahmer et al., 2012; Hamid et al., 2013; Hodi et al., 2010; Topalian et al., 2012).  
Although mAbs that block these immune checkpoint molecules represent a new 
therapeutic paradigm for cancer, mechanisms of PD-1 or CTLA-4 resistance are poorly 
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understood. Pre-existing T cell antitumor immunity has been hypothesized as a 
prerequisite (Gajewski et al., 2010; Ji et al., 2011; Zamarin et al., 2014). The majority of 
cancer patients treated with these agents alone do not clinically respond, and some tumor 
types, such as pancreatic carcinoma, are fully refractory (Brahmer et al., 2012; Le et al., 
2013; Royal et al., 2010). Although the combination of αPD-1 and αCTLA-4, either 
together or in sequence, may improve tumor response rates in melanoma, as suggested by 
results of a recent clinical trial, a large fraction of patients on this trial still failed to 
respond (Wolchok et al., 2013). Melanoma, for which the best response rates with single-
agent checkpoint inhibition have been observed, segregates into distinct subpopulations 
based on the tumor immune microenvironment, and an immune gene signature predicts 
response to ipilimumab in melanoma patients (Gajewski et al., 2010; Ji et al., 2011). 
Tumor PD-L1 expression in melanoma correlates spatially with the presence of 
infiltrating CD8+ T cells, suggesting that tumor cells upregulate PD-L1 in response to 
immune pressure, a hypothesis termed adaptive immune resistance (Taube et al., 2012). 
Evidence of similar pathophysiology has been observed in carcinomas of the lung, 
kidney, and head and neck (Lyford-Pike et al., 2013; Taube et al., 2014). Recent work in 
a mouse model of melanoma demonstrates that CD8+ T cell-derived IFN-γ drives PD-L1 
expression in malignant cells; this work is corroborated by a recent report indicating that 
CD8+ T cells, PD-1, and PD-L1 all correlate with survival in patients treated with αPD-1, 
and that this immune signature can predict responses (Spranger et al., 2013; Tumeh et al., 
2014) . Furthermore, IFN-γ and IFN-γ-inducible genes are upregulated in pretreatment 
biopsies of responding melanoma patients compared to nonresponders treated with αPD-
L1 (Herbst et al., 2014). These data suggest that the efficacy of checkpoint inhibitors may 
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require the presence of an endogenous antitumor T cell response. In fact, the 
augmentation of antitumor T cell responses with vaccines, peritumoral poly(I:C), or 
intratumoral oncolytic virus has been shown to improve baseline responses to checkpoint 
inhibitors in murine models of melanoma, ovarian cancer, and colon cancer (Bald et al., 
2014; Duraiswamy et al., 2013; Zamarin et al., 2014; Zhou et al., 2010). In models which 
are fully refractory to αPD-1 or αCTLA-4 alone, however, it remains unclear whether a 
vaccine approach can potentiate tumor rejection and long-term survival. 
In the studies reported here, I tested the hypothesis that failed immune recognition 
or poor T cell priming is responsible for the lack of responses to checkpoint inhibitors in 
PDA. I focused on the KPC mouse model of spontaneous PDA in which expression of 
oncogenic KrasG12D and mutant p53 is targeted to the pancreas by Cre recombinase under 
the control of the pancreatic specific promoter Pdx-1 (Hingorani et al., 2005). This model 
recapitulates the molecular, histologic and immune parameters of the human disease 
(Bayne et al., 2012; Beatty et al., 2011; Clark et al., 2007; 2008; Hingorani et al., 2005). 
The clinical relevance of our findings in the murine models was confirmed by analysis of 
human PDA tumors. I induced T cell immunity using an agonistic αCD40 in combination 
with chemotherapy (Elgueta et al., 2009; Nowak et al., 2003), and compared the impact 
and mechanism of αPD-1/αCTLA4 mAb with or without this “vaccine”, examining only 
well-established tumors. 
 
RESULTS 
PD-1/PD-L1 axis is highly expressed in murine and human PDA 
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To understand the biology of the PD-1/PD-L1 pathway in pancreatic carcinoma, I first 
interrogated the expression of PD-1 and PD-L1 using the KPC spontaneous genetic 
model of PDA. Within the microenvironment of KPC tumors few infiltrating T cells were 
observed, as has previously been reported (Figure 1) (Beatty et al., 2011; Clark et al., 
2008). However, these T cells prominently expressed PD-1 in all subsets including CD8+, 
CD4+, and regulatory (Foxp3+) T cells, as determined by flow cytometry (Figure 2). For 
each subset, PD-1 expression was significantly higher in the tumor than in the 
corresponding populations in the spleens of the same tumor-bearing mice (Figure 2). In 
the absence of a distinct marker for pancreatic epithelial cells in the KPC model, I 
identified tumor cells with negative gating, excluding leukocytes (CD45), endothelial 
cells (CD31), and mesenchymal populations (CD90) by flow cytometry of single cell 
suspensions of KPC tumors. KPC pancreatic tumor cells exhibited moderate expression 
of PD-L1 on more than 40% of the identified tumor cells (Figure 3). PD-L1 was also 
expressed by 10%-50% of normal pancreatic epithelial cells identified in C57BL/6 wild-
type mice in the absence of cancer. In contrast to moderate expression of PD-L1 on tumor 
cells in the KPC model, DCs and macrophages in the KPC tumor microenvironment 
expressed very high levels of PD-L1, statistically significantly higher compared to PD-L1 
expression of these same APC populations in the spleens of KPC mice (Figure 4). 
To assess whether these findings in the KPC model were consistent with human 
PDA, I collaborated with Dr. Furth and developed a validated immunohistochemical 
assay for PD-L1 expression in human tissues and examined human PDA samples for PD-
L1 expression. In primary tumors from patients with resected PDA, we observed 
moderate to intense expression of PD-L1 on tumor cells in 4 of 8 (50%) resection 
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specimens (Figure 5). We also observed that T cells in human PDA were relatively rare 
within malignant foci (mean ratio of CD8+ T cells per μm2 of tumor vs. non-tumor areas 
was 0.065 + 0.052, range of 0.000-0.170) – again consistent with the KPC model (Beatty 
et al., 2011). PD-L1 expression on tumor cells in human samples did not correspond 
spatially with the presence of CD8+ T cells (Figure 5). There was no statistical correlation 
between intensity or extent of tumor PD-L1 expression and intratumoral CD8+ T cell 
infiltration (p=0.69) (Figure 6). For example, of the two tumors with the most 
intratumoral CD8+ T cells, one had intense and the other had minimal PD-L1 expression 
(Figure 6). These data in human PDA are in contrast to the correspondence of tumor PD-
L1 expression and T cell infiltration previously reported for tumors from patients with 
melanoma or kidney or head and neck carcinoma (Lyford-Pike et al., 2013; Taube et al., 
2012; 2014).  
 
PD-1 is as highly expressed in murine PDA as it is in chronic LCMV infection 
To evaluate the potential role of the PD-1/PD-L1 axis in mediating immune suppression 
in PDA, I first generated a PDA cell line from a backcrossed KPC mouse and established 
subcutaneous PDA tumors in immune competent C57BL/6 mice. Histopathological 
examination of established tumors from this model showed recapitulation of both the 
cellular and extracellular components of spontaneous KPC tumors, with prominent 
deposition of a dense desmoplastic stroma and comparable populations of infiltrating 
immunosuppressive leukocytes, including  a robust infiltrate of F4/80+ macrophages 
(Figure 7). I then examined expression of PD-1 on T cells from subcutaneous tumor-
bearing mice, but did so by simultaneously examining PD-1 expression on T cells from a 
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parallel cohort of mice in which chronic LCMV infection had been established with 
LCMV clone 13 (Figure 8). In many ways, this model of chronic LCMV infection has 
served as a gold standard for understanding the transcriptional basis and phenotype of 
exhausted CD4+ and CD8+ T cells (Barber et al., 2006; Blackburn et al., 2009; Crawford 
et al., 2014; Doering et al., 2012; Paley et al., 2012; Wherry et al., 2007). Two of the 
most highly upregulated genes mechanistically linked to T cell exhaustion in response to 
chronic infection in this model are PD-1 and Lag-3 (Blackburn et al., 2009). I therefore 
compared coexpression of these markers on intratumoral and splenic T cells in mice 
bearing established subcutaneous PDA tumors with splenic T cells from mice with 
chronic LCMV (Figure 8). Intratumoral CD8+, CD4+, and regulatory T cells co-expressed 
PD-1 and Lag-3 at levels comparable to the corresponding T cell populations in LCMV-
infected mice (Figure 9). Furthermore, PD-1 expression was statistically higher on tumor 
infiltrating T cells than on T cells from chronically infected mice, demonstrating the 
prominence of this inhibitory receptor in the PDA microenvironment (Figure 10). This 
phenotype was restricted to the tumor, as splenic T cells from tumor-bearing mice did not 
coexpress PD-1 or Lag-3. Thus, T cell expression of PD-1 is higher in the PDA tumor 
microenvironment than it is in chronic LCMV infection. 
I also examined PD-L1 expression in the subcutaneous PDA model. About 60% 
to 70% of tumor cells isolated from established tumors expressed PD-L1 (Figure 11), 
similar to the expression of PD-L1 on this cell line grown in vitro (Figure 14). These 
findings were confirmed using a YFP+ tumor cell line established from a pancreatic 
tumor isolated from a KPCY genetically engineered mouse; in this model, YFP serves as 
a validated lineage tracer for pancreatic epithelium (Rhim et al., 2012). After 
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subcutaneous tumor implantation and growth in syngeneic hosts for 14 days, I found that 
on average 66.7% of YFP+ tumors cells expressed PD-L1, as measured by flow 
cytometry (Figure 12).  Moreover, high levels of PD-L1 on both DCs and macrophages 
were observed in the tumor microenvironment of the KPC subcutaneous tumors (Figure 
13), mirroring PD-L1 expression on these APC subsets in spontaneous tumors of KPC 
mice. Both a higher percentage of PD-L1+ APCs and a higher (~3-4-fold) mean 
fluorescence intensity (MFI) of PD-L1 was observed compared to the corresponding 
APC populations in the spleens of the same mice (Figure 13). These data indicate that 
PD-L1 expression is prevalent in the PDA microenvironment, as these APC populations 
make up as much as 8%-25% of the cellular composition of these tumors (Figure 7). 
  
Tumor PD-L1 expression in PDA is not IFN-γ dependent 
PD-L1 expression in human melanoma and HNSCC correlates spatially with T cell 
infiltration (Lyford-Pike et al., 2013; Taube et al., 2012), and ,in melanoma, tumor 
expression of PD-L1 is dynamically upregulated in response to IFN-γ secreted by these 
infiltrating CD8+ T cells (Spranger et al., 2013). To determine whether this same 
mechanism is responsible for PD-L1 expression in PDA, I first assessed the ability of our 
PDA cell lines to upregulate PD-L1 in response to IFN-γ; in vitro, IFN-γ stimulation 
resulted in increased expression of PD-L1 by PDA cells in each of 8 separate KPC 
derived cell lines (Figure 14). To then assess the role of this pathway in vivo, I evaluated 
tumor and APC PD-L1 expression in the presence or absence of T cells and IFN-γ. 
Subcutaneous PDA tumors were established in mice that were genetically lacking IFN-γ, 
systemically depleted of CD4+ and CD8+ T cells, or both. Tumor growth in vivo was the 
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same for each condition compared to control (Figure 15). Analysis of these tumors 
showed no significant change in tumor PD-L1 expression (either percentage or MFI) with 
regard to IFN-γ or T cell status (Figure 16). Analysis of the APC populations in these 
tumors indicated that IFN-γ plays a minor role in the regulation of PD-L1 expression on 
intratumoral DCs and macrophages. Small but statistically significant differences were 
observed in the percentage and MFI of PD-L1 expression on intratumoral APCs between 
IFN-γ sufficient and deficient hosts (Figure 17). In contrast, the presence or absence of T 
cells did not affect PD-L1 expression of APCs regardless of host IFN-γ status (Figure 
17), recapitulating the lack of correspondence between CD8+ T cells and PD-L1 
expression in human PDA (Figure 6). 
 
T cell stimulation with CD40/gemcitabine/nab-paclitaxel converts PDA from being 
fully refractory to highly sensitive to checkpoint blockade  
Given the prominent expression of PD-1 and PD-L1 in the PDA tumor 
microenvironment, I tested the antitumor in vivo efficacy of PD-1 blocking mAb either 
with or without CTLA-4 blocking mAb (Figure 18). Even with αCTLA-4, αPD-1 did not 
impact tumor growth or survival (Figure 19), even though a comparable αPD-1 dosing 
schedule reproducibly improves clinical outcomes in mice chronically infected with 
LCMV clone 13 (Barber et al., 2006; Blackburn et al., 2008). This finding was surprising 
given the fact that tumor associated T cells express even more PD-1 than the T cells in 
LCMV infected mice (Figure 10). However, this lack of antitumor efficacy is similar to 
the lack of responses observed to date in patients with advanced PDA treated with αPD-
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L1 or αCTLA-4, suggesting that this model recapitulates this immunologic aspect of the 
human disease (Brahmer et al., 2012; Le et al., 2013; Royal et al., 2010).  
These same reagents have shown efficacy in patients in other malignancies; one 
possible distinction may be the presence of an antitumor immune response at baseline in 
subsets of these patients (Gajewski et al., 2010; Galon et al., 2013). I therefore 
hypothesized that the induction of a T cell response would be required to overcome 
refractoriness to αPD-1 and αCTLA-4 in PDA and achieve clinical benefit. It has been 
well-established that an agonist αCD40 antibody facilitates cancer vaccines (Cho and 
Celis, 2009) and can synergize with chemotherapy-induced immunogenic cell death to 
initiate a T cell-dependent antitumor immune response and tumor regression, providing a 
vaccine effect in model systems for which a tumor-rejection antigen is not characterized 
(Buhtoiarov et al., 2010; Nowak et al., 2003). Here, we chose to examine the 
chemotherapeutic combination of gemcitabine and nab-paclitaxel because these agents 
are recently FDA-approved for the treatment of metastatic PDA (Von Hoff et al., 2013), 
and gemcitabine has been previously been shown to cooperate immunologically with 
αCD40 for the induction of T cell immunity (Nowak et al., 2003). Treatment of mice 
with established subcutaneous PDA tumors with αCD40/chemotherpay altered the 
phenotype of tumor infiltrating T cells, although the percent of T cells infiltrating the 
tumors did not change. There were statistically significantly fewer CD8+ T cells that co-
expressed the inhibitory PD-1 and Lag-3 markers in treated tumors, and more 
proliferating CD4+ and CD8+ T cells were found in the tumors of treated mice compared 
to controls (Figure 20). 
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As is true for the vast majority of patients with metastatic PDA, the combination 
of gemcitabine and nab-paclitaxel at the maximum tolerated dose did not induce 
regression of established subcutaneous PDA tumors (data not shown); however, the 
addition of αCD40 to this chemotherapy regimen inhibited tumor growth and improved 
survival compared to control-treated tumor-bearing mice (Figure 21). These effects were 
T cell-dependent, as αCD40 plus chemotherapy failed to impact tumor growth in mice 
depleted of CD8+ and CD4+ cells (Figure 21). The addition of αPD-1, αCTLA-4, or both 
to treatment with αCD40/chemotherapy significantly improved the ability of 
αCD40/chemotherapy to inhibit tumor growth, and led to an increase in survival in mice 
bearing subcutaneous PDA tumors (Figure 21). Moreover, the addition of checkpoint 
inhibitors to αCD40/chemotherapy led to complete rejection of established tumors and 
long-term tumor-free survival in significant proportions of mice treated (Figure 22). The 
highest rates of tumor regression were observed in mice treated with both αPD-1 and 
αCTLA-4, with 39% (17 of 44) of mice achieving long-term complete remission and 
survival after treatment with all three antibodies plus chemotherapy (Figure 22). Tumor 
growth was delayed in nearly all mice treated with αCD40/chemotherapy and αPD-
1/αCTLA-4, even in those mice not completely rejecting their tumors, suggesting that the 
tumor response rate is even higher than the tumor rejection rate in this model (Figure 23).  
 
Rejection of PDA tumors by αCD40/chemotherapy and checkpoint blockade is T 
cell-mediated 
To determine whether the antitumor effect I observed was T cell-mediated, I repeated the 
study with a cohort of mice depleted of CD4+ and CD8+ T cells, starting on the day prior 
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to the initiation of therapy. In the absence of T cells, there was a loss of the tumor growth 
inhibition and survival advantage of treatment, and no T-cell depleted mice rejected the 
tumor or survived long-term (Figure 24). 
To understand the effect of our treatment on intratumoral T cell populations, I 
treated cohorts of tumor-bearing mice with αPD-1/αCTLA-4, αCD40/chemotherapy, 
both, or neither (control), and sacrificed mice one week after treatment with αCD40 (or 
control) to analyze tumors for T cell infiltration. Tumors from mice treated with αPD-
1/αCTLA-4 plus αCD40/chemotherapy had a significantly increased (7-fold) CD8:Treg 
ratio compared to control-treated mice (Figure 25). This phenotype was also seen in some 
of the mice treated with αCD40/chemotherapy or αPD-1/αCTLA-4, although neither of 
these groups exhibited as consistent of an increase in the CD8:Treg ratio as the mice 
treated with αPD-1/αCTLA-4 plus αCD40/chemotherapy (Figure 25). The CTLA-4 mAb 
clone 9H10 partly mediates its antitumor effect by depletion of Tregs, which express 
CTLA-4 (Simpson et al., 2013); however, I observed that mice treated with αPD-
1/αCTLA-4 alone did not have a significantly decreased percentage of Tregs among 
CD4+ T cells (Figure 25) or among total CD45+ cells (data not shown). Rather, the 
administration of αCD40/chemotherapy (either with or without αPD-1/αCTLA-4) was 
associated with a significant decrease in Treg percentages compared to control treated 
mice (Figure 25). These data suggest that αCD40/chemotherapy changes the immune 
microenvironment in this PDA model and leads to a decreased percentage of Tregs and 
increased CD8:Treg ratio, an effect that is augmented further with the addition of 
checkpoint blockade. The greatest changes in Treg percentage and CD8:Treg ratio were 
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associated with the highest rates of complete remission and long-term survival across 
cohorts reported in Figure 22. 
One theoretical benefit of cancer immunotherapy is the induction of an antitumor 
memory T cell response with the capability to reject recurrent or metastatic disease. To 
test whether mice that had completely rejected established PDA tumors had developed 
immune memory, I rechallenged cohorts of mice that were in long-term complete 
remission with the same number of cells of the same PDA tumor line but on the opposite 
flank (Figure 26). I observed that 67% to 86% of such mice rejected the PDA tumor cells 
implanted on the opposite flank without any therapy (Figure 26), consistent with 
immunological memory. Because the most likely effector memory T cell population 
mediating this effect is a CD8+ T cell, I further studied mice that had rejected both the 
initial tumor and the first rechallenge on the opposite flank, and either depleted these 
mice of CD8+ T cells or administered an isotype control. All mice were then rechallenged 
with the same number of cells of the same cell line on the original flank. All mice 
depleted of CD8+ T cells rapidly developed progressively growing tumors at the site of 
second rechallenge, whereas 4 of 6 isotype-treated mice rejected this second tumor 
rechallenge (Figure 27). This effect translated into a significant difference in overall 
survival after second rechallenge (Figure 27). These data indicate that combination 
immunotherapy can establish CD8-dependent immunological memory against PDA with 
curative potential.  
 Given the mechanistic understanding of the agonist αCD40 mAb and the 
chemotherapeutics gemcitabine and nab-paclitaxel, it seemed likely that the αCD40 arm 
of the treatment was key to potentiating the efficacy of checkpoint inhibitors in this 
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model (Diehl et al., 1999; French et al., 1999). In order to test this hypothesis, I treated 
tumor bearing mice with αCD40, gemcitabine/nab-paclitaxel, or both, and treated all 
mice with both αPD-1 and αCTLA-4, monitoring the mice for tumor growth and survival. 
Both cohorts treated with chemotherapy showed an early stabilization of tumor size in the 
aftermath of therapy, as compared to the cohort not receiving chemotherapy (Figure 
28A). However, in the mice not receiving αCD40 treatment the tumor growth inhibition 
of the chemotherapy was short lived and the tumors continued to grow after a few days. 
In both groups treated with αCD40 and checkpoint inhibitors, tumors began to regress 
within a few days of αCD40 therapy, regardless of whether they had been treated with 
chemotherapy (Figure 28A). Ultimately, tumors were completely rejected in all 3 groups, 
but a clear pattern emerged; mice treated with αCD40 and checkpoint inhibitors rejected 
their tumors at much higher rates than the cohort which was treated with just 
chemotherapy and αPD-1/αCTLA-4 (Figure 28B). These data indicate that αCD40 is 
more important than chemotherapy in potentiating the efficacy of checkpoint inhibitors in 
this tumor model. Nevertheless, given that gemcitabine and nab-paclitaxel are a standard 
of care for patients with PDA, I chose to move forward with my studies in the KPC 
model using the combination of chemotherapy and αCD40 rather than αCD40 alone to 
maintain the translational relevance of this work. 
 
αCD40/chemotherapy cooperates with PD-1 blockade to improve survival of mice 
with established tumors in the KPC genetic model of PDA 
Having observed that the induction of T cell immunity via αCD40/chemotherapy 
potentiates the efficacy of checkpoint inhibitors in the subcutaneous model of PDA, I 
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tested this approach in the autochthonous KPC model of PDA. Observations in the KPC 
model have previously been shown to predict clinical responses in PDA patients treated 
with the same or homologous agent (Beatty et al., 2011; Provenzano et al., 2012; Rhim et 
al., 2014; Shepard et al., 2012). I therefore performed a randomized, controlled study of 
checkpoint inhibition in combination with αCD40/chemotherapy in cohorts of tumor-
bearing KPC mice. Given the striking expression of PD-1 and PD-L1 in the KPC tumor 
microenvironment, I chose to test our hypothesis using the αPD-1 mAb. Mice diagnosed 
with pancreatic tumors of 30 mm3-150 mm3 were randomized to treatment with αCD40 
plus gemcitabine/nab-paclitaxel, αPD-1, αCD40/chemotheray plus αPD-1, or control (as 
described in Materials and Methods and summarized in Figure 29A), using the same dose 
and schedule as used for mice in the subcutaneous PDA studies. I observed a statistically 
significant increase in overall survival for mice receiving αCD40/chemotherapy plus 
αPD-1 compared to control (p=0.015, log-rank Mantel-Cox) (Figure 29B). The effect was 
large: combination treatment nearly doubled median overall survival from 23 days in the 
control arm to 41.5 days in the experimental arm with a hazard ratio of 0.334 (0.0584-
0.657, 95% confidence interval). Neither PD-1 alone nor αCD40/chemotherapy 
significantly improved overall survival. These data suggest that as predicted by my 
findings in the subcutaneous PDA model, the induction of a T cell response is needed to 
observe antitumor effects using αPD-1 in PDA. 
Although treatment was well tolerated in the vast majority of mice, in 6.3% of 
mice treated with αCD40/chemotherapy and at least one checkpoint blocking mAb I 
noted clinical deterioration consistent with an infectious syndrome (Figure 30). 
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CONCLUSIONS AND DISCUSSION 
The clinical success of checkpoint inhibitors, including FDA approval of ipilimumab and 
pembrolizumab in melanoma, has prompted investigations to replicate this result even 
more broadly in oncology. Early findings, however, suggest that many tumors are 
resistant, with some tumors such as pancreatic carcinoma appearing completely 
refractory to checkpoint blockade alone (Brahmer et al., 2012; Le et al., 2013; Royal et 
al., 2010). Elucidation of the biological mechanisms underlying this resistance, and 
strategies to overcome it therapeutically, are only beginning to emerge. Here, using a 
genetically engineered mouse model (GEMM) of PDA, which like human PDA exhibits 
minimal spontaneous immunity, I demonstrate that despite robust expression of PD-1 and 
PD-L1 in the tumor microenvironment, treatment with αPD-1 with or without αCTLA-4 
fails to improve the survival of mice or slow the growth of PDA tumors. These results 
replicate the lack of effect observed to date in PDA patients treated with analogous agents 
(Brahmer et al., 2012; Le et al., 2013; Royal et al., 2010). However, in the context of 
αCD40/chemotherapy deployed as a vaccine, I demonstrate that the induction of T cell 
immunity converts PDA from a tumor that is completely refractory to αPD-1 and/or 
αCTLA-4 into one in which checkpoint blockade controls tumor growth and significantly 
improves survival in a CD8+ T cell dependent manner. In particular, 
αCD40/chemotherapy plus αPD-1 nearly doubles the median overall survival in 
genetically engineered KPC mice with pre-established spontaneous pancreatic tumors. 
Moreover, the capability of treated mice to reject second and third subcutaneous tumor 
challenges in a CD8+ T cell-dependent fashion, thereby rendering long-term survival, 
suggests the establishment of antitumor immune memory with curative potential. These 
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findings indicate that poorly immunogenic tumors, epitomized by the KPC pancreatic 
tumor model, can nevertheless be controlled by the adaptive immune system provided a 
dual approach of therapeutic T cell induction and checkpoint blockade is utilized.  
Immunologically, the PDA tumor microenvironment is considered especially 
suppressive, but increasingly, there is an appreciation from studies in KPC and other 
PDA models of an underlying sensitivity of PDA tumor cells to T cell cytotoxicity 
(Vonderheide and Bayne, 2013). Unlike melanoma, PDA does not commonly present 
with a robust tumor infiltration of CD8+ T cells (Bernstorff et al., 2001; De Monte et al., 
2011; Fukunaga et al., 2004; Hiraoka et al., 2006). Instead of effector T cell infiltration in 
the tumor, Dr. Vonderheide and others have observed in genetically engineered mouse 
models of PDA, a prominent network of immunosuppressive macrophages, MDSCs, and 
Tregs that becomes dominant even at the earliest stages of disease (Bayne et al., 2012; 
Beatty et al., 2011; Clark et al., 2007; 2008; Zhang et al., 2014). I demonstrated that PD-1 
is expressed on more T cells in the KPC tumor microenvironment than it is systemically 
in mice chronically infected with LCMV in which treatment with αPD-1 successfully 
reverses T cell exhaustion (Figure 10) (Barber et al., 2006). I propose therefore, that the 
lack of responses to treatment with checkpoint inhibitors in KPC mice likely reflects a 
tumor microenvironment without an underlying antitumor T cell response, making a 
response to αPD-1 or αCTLA-4  alone mechanistically unlikely. 
Thus, in this study I interpret the antitumor effects of αCD40/chemotherapy plus 
αPD-1/αCTLA-4 as a strategy that overcomes acquired immune privilege in PDA. To be 
sure, other pathways in the PDA tumor microenvironment may also be “targetable” as 
part of novel immunotherapeutic approaches. For example, derailing non-tumor cell 
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intrinsic immunosuppressive elements in the PDA microenvironment (such as 
macrophages, fibroblasts, and MDSC) permits trafficking of CD8+ T cells into the tumor 
and can induce tumor regression (Bayne et al., 2012; Feig et al., 2013; Zhu et al., 2014). 
These strategies can now be rationally combined with αCD40/chemotherapy plus αPD-
1/αCTLA-4 and tested for synergy and survival benefit in the KPC model. 
Despite the 80% increased overall survival observed in KPC mice treated with 
αCD40/chemotherapy and αPD-1 compared to controls, all mice succumbed to their 
disease. It is worth noting that there are no published reports of cures of KPC mice 
bearing established invasive tumors. A few groups have reported improved overall 
survival (without cures) with treatment in this model, including the recent demonstration 
that the vitamin D analogue calcipotriol improves survival by 57% (Olive et al., 2009; 
Provenzano et al., 2012; Sherman et al., 2014). Given the difference I observed in the 
response to treatment between the subcutaneous and KPC PDA models, I hypothesize 
that there is additional complexity in the tumor microenvironment of spontaneous KPC 
tumors which limits therapeutic responses. Potential other immunosuppressive pathways 
contributing to treatment resistance include MDSCs, macrophages, and FAP+ 
mesenchymal cells, among others (Bayne et al., 2012; Feig et al., 2013; Pylayeva-Gupta 
et al., 2012; Zhu et al., 2014). My observations have relevance to patients with PDA not 
only because of our observations of PD-L1 expression in human PDA but also because of 
the high fidelity of the KPC model to human pancreatic cancer and its capability to 
predict the clinical potential of reagents (Beatty et al., 2011; Provenzano et al., 2012; 
Rhim et al., 2014; Sherman et al., 2014). 
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In the absence of a defined tumor antigen in our KPC model, I therapeutically 
induced T cells with chemotherapy followed by an agonist αCD40, a sequence previously 
described to injure tumor cells, release tumor antigen, and license APCs (Nowak et al., 
2003). Although non-chemotherapeutic agents, such as targeted therapies, may also 
synergize with αCD40 (Ho et al., 2014), gemcitabine in particular cooperates with 
αCD40 (Nowak et al., 2003). Here, I added nab-paclitaxel given the recent regulatory 
clinical approval of gemcitabine with nab-paclitaxel for the treatment of metastatic PDA. 
Although, as previously shown, αCD40 alone can generate an antitumor macrophage (but 
not T cell) response in vivo (Beatty et al., 2011), the addition of gemcitabine, nab-
paclitaxel, and αPD-1 enabled a T cell response. I demonstrated that while αCD40 is 
necessary for the potentiation of checkpoint inhibitor efficacy, chemotherapy alone does 
not allow checkpoint inhibitor treatment to induce rejection of tumors and long term 
survival (Figure 28). In this study, a greater percentage of mice treated with αCD40/αPD-
1/αCTLA-4 rejected their tumors than those who also were treated with chemotherapy, 
although this difference was not significant; this could potentially be due to 
chemotherapeutic ablation of rapidly proliferating immune cells. Nevertheless, for the 
sake of translational relevance I conducted most of the studies in the setting of 
chemotherapy as it is standard of care for PDA patients; further investigation is needed to 
determine the role of chemotherapy in the induction of a T cell response. Moreover, I 
made these observations in the setting of pre-established tumors and an autochthonous 
tumor microenvironment, two additional elements of this experimental system relevant to 
translation to the clinic. 
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With increasingly potent immune therapies, toxicity can become an important and 
limiting issue. For example, the combination of nivolumab (αPD-1) with ipilimumab 
(αCTLA-4) is associated with a higher rate of grade 3 and 4 toxicities than either agent 
alone (Wolchok et al., 2013). During the studies reported here, I noted a few cases of 
treatment-related opportunistic infection of the CNS.  This pathology was observed only 
in mice treated with both CD40/chemotherapy plus one or more checkpoint inhibitors, 
but even then only in certain cohorts of mice imported from one vendor and not in other 
imported mice of the same genetic background that received the same treatment (Figure 
30). Mice bred in our facility and treated with this same combination of reagents never 
presented with this clinical syndrome (n=24). Pathologic analyses of mice exhibiting 
clinical deterioration indicated inflammation of the CNS which was neutrophilic and 
associated with evidence of bacterial infection, and not lymphocytic or otherwise notable 
for T cell autoimmunity. The overall impression was that of vendor-related commensal 
bacteria which became pathologic in the context of immune-altering treatment, providing 
a note of caution as new immunotherapy combinations are tested in patients in early 
phase trials. 
In summary, induction of T cell immunity overcomes resistance to PD-1 and 
CTLA-4 blockade and improves survival in pancreatic carcinoma. My work suggests 
than an understanding of the underlying immunobiology of solid tumors may help in 
determining which malignancies may benefit from checkpoint inhibition, and which may 
necessitate combinatorial immunotherapy to first induce an antitumor T cell response. 
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Figure 1. Tumor infiltrating T cells are rare in pancreatic tumors of KPC mice.  
Pancreatic tumors of KPC mice were evaluated by flow cytometry for the presence of (A) 
CD4+ (gated on live, CD3+CD4+) and (B) CD8+ (gated on live, CD3+CD8+) T cells. 
CD4+and CD8+ T cells are quantified as percentage of all live events (A and B). (C) 
Regulatory T cells (Tregs;  gated on live, CD3+ CD4+ FoxP3+) are shown as percentage 
of CD4+ T cells. 
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Figure 2. PD-1 is highly expressed on all tumor infiltrating T cell subsets in KPC 
tumors. Representative histograms and quantification of PD-1 expression on tumor 
infiltrating (A) CD8+ (gated on live, CD45+, CD3+, CD8+), (B) CD4+ (gated on live, 
CD45+, CD3+, CD4+), or (C) regulatory (Tregs; gated on live, CD45+, CD3+, CD4+, 
FoxP3+) T cells in tumors (n=6-11) or spleens (n=4-17) from tumor bearing KPC mice. 
**p≤ 0.01, ****p≤ 0.0001. 
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Figure 3. PD-L1 is moderately expressed on pancreatic tumor cells in vivo in KPC 
tumors. Representative histograms and quantification of PD-L1 expression on tumor 
cells and normal pancreatic epithelial cells (gated on live, CD45neg, CD31neg, CD90neg) in 
tumors (n=4) from tumor bearing KPC mice and normal pancreata (n=5) from healthy 
C57BL/6 mice. 
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Figure 4. PD-L1 is highly expressed on dendritic cells and macrophages in 
pancreatic tumors of KPC mice. Representative histograms and quantification of  
PD-L1 expression on (A) dendritic cells (DCs; gated on live, CD45+, F4/80neg, CD19neg, 
CD11c+) and (B) macrophages (Macs; gated on live, CD45+, F4/80+) in tumors (n=11) or 
spleens (n=25) from tumor bearing KPC mice. **p≤ 0.01, ***p≤ 0.001. 
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Figure 5. PD-L1 is expressed in human PDA; few CD8+ T cells infiltrate human 
PDA. Histology of PD-L1 expression and CD8+ T cell infiltration in human pancreatic 
cancer sections. (A) PD-L1 expression on malignant cells of a PDA tumor (PD-L1 
expression score of 4+ (intense), see Materials and Methods; 40x and 400x magnification 
for top and bottom panels, respectively). (B) CD8 expression in serial section of the 
tumor in (A), demonstrating few tumor-infiltrating CD8+ T cells (40x magnification).  
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Figure 6. In human PDA there is no correlation between PD-L1 expression and 
CD8+ T cell infiltration. Plot describing correlation between intratumoral CD8 count 
and tumor PD-L1 score (n=8). p=0.69. 
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Figure 7. Subcutaneous PDA tumors recapitulate KPC tumor immune 
microenvironment. Pancreatic tumors of KPC mice and subcutaneously grown PDA 
tumors were evaluated by flow cytometry for the presence of (A) macrophages (gated as 
above), (B) B Cells (gated on live, CD45+ F4/80neg CD19+), and (C) DCs (gated as 
above). All populations are quantified as percentage of all live events. *p≤ 0.05. 
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Figure 8. Experimental design for establishment of subcutaneous PDA tumors or 
chronic LCMV clone 13 infection simultaneously in 2 cohorts of C57BL/6 mice. 
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Figure 9. Co-expression of PD-1 and Lag-3 on T cell populations from mice with 
LCMV Clone 13 infection or subcutaneous PDA tumors. Representative flow plots 
and quantification of co-expression of PD-1 and Lag-3 on (A) CD8+ (gated on live, 
lymphocytes, B220neg, NK1.1neg, CD8+), (B) CD4+ (gated on live, lymphocytes, B220neg, 
NK1.1neg, CD4+) and (C) regulatory (Tregs; gated on live, lymphocytes, B220neg, 
NK1.1neg, CD4+, FoxP3+)  T cells from spleens of mice infected with LCMV Clone 13 
(Cl-13; day 30) or the tumors and spleens of mice bearing PDA tumors (day 14). 
  
57 
A      B 
C
l-1
3 
S
pl
ee
n
Tu
m
or
Tu
m
or
 S
pl
ee
n
%
o
f 
C
D
8
s
 P
D
-1
+
 
C
l-1
3 
S
pl
ee
n
Tu
m
or
Tu
m
or
 S
pl
ee
n
%
o
f 
C
D
4
s
 P
D
-1
+
 
C 
 
Figure 10. PD-1 expression is greater on tumor infiltrating T cells than 
corresponding populations in LCMV infected mice. Quantification of PD-1 expression 
on (A) CD8+, (B) CD4+, and (C) regulatory T cells (all gated as above) from spleens of 
mice infected with LCMV Cl-13 (day 30) or the tumors and spleens of mice bearing PDA 
tumors (day 14). One-way ANOVA: %of CD8s PD-1+ (A), p≤ 0.0001; %of CD4s PD-1 + 
(B), p≤ 0.0001; %of Tregs PD-1+ (C), p≤ 0.0001. Post hoc test p values are indicated 
where significant as **p≤ 0.01, ****p≤ 0.0001. 
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Figure 11. PD-L1 is moderately expressed in vivo on tumor cells in subcutaneous 
PDA tumors. Representative histograms and quantification of PD-L1 expression on 
tumor cells in subcutaneous PDA tumors (day 14), gated as in Figure 3.  
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Figure 12. Moderate PD-L1 expression on lineage labeled PDA tumor cells in vivo. A 
PDA cell line generated from a backcrossed KPCY mouse (as described in Materials and 
Methods) was implanted in immune competent C57BL/6 mice (n=4) and mice were 
sacrificed on day 15 after implantation. Representative flow plot and quantification of 
PD-L1 expression on lineage labeled tumor cells is shown (gated on Live, CD45neg 
YFP+). 
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Figure 13. PD-L1 is highly expressed on dendritic cells and macrophages in 
subcutaneous PDA tumors. Representative histograms and quantification of PD-L1 
expression on (A) dendritic cells (DCs) and (B) macrophages (Macs) in subcutaneous 
PDA tumors or spleens from the same mice (day 14), gated as above. (MFI=mean 
fluorescence intensity). ****p≤ 0.0001. 
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Figure 14. PD-L1 expression on PDA cell lines can be upregulated by IFN-γ in vitro. 
(A) Representative histogram of a KPC-derived PDA cell line interrogated for PD-L1 
expression in vitro with or without IFN-γ in the culture, and (B) quantification of 8 
distinct KPC-derived PDA cell lines interrogated for PD-L1 expression in vitro with or 
without IFN-γ. 
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Figure 15. Tumor growth of subcutaneous PDA tumors is not significantly affected 
by host IFN-γ or T cell status. Tumor weights in grams of tumors grown in C57BL/6 
(B6) or IFN-γ-/- (IFN-γ ko) mice with or without CD4+ and CD8+ T cell depletion (TCD) 
(day 16; n=6-8 mice per cohort).One-way ANOVA: p=0.486. 
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Figure 16. Tumor cell PD-L1 expression is not affected by IFN-γ or T cell status of 
host in vivo. (A) Quantification and (B) MFI of PD-L1 expression on tumor cells from 
subcutaneous PDA tumors established in either C57BL/6 (B6) or IFN-γ-/- (IFN-γ ko) 
mice with or without CD4+ and CD8+ T cell depletion (TCD) (day 16; n=6-8 mice per 
cohort). One-way ANOVA p values indicated. 
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Figure 17. Host IFN-γ status has small effect on dendritic cell and macrophage PD-
L1 expression in subcutaneous PDA tumors. Quantification and MFI of PD-L1 
expression on (A) dendritic cells (DCs) and (B) macrophages (Macs) in subcutaneous 
PDA tumors grown in either B6 or IFN-γ ko mice with or without TCD (day 16; n=6-8 
mice per cohort). One-way ANOVA: %DCs PD-L1+ (A), p=0.015; DC PD-L1 MFI (B), 
p=0.0039; %Macs PD-L1+ (C), p=0.58; Macs PD-L1 MFI (D), p=0.0007. Post hoc test p 
values are indicated where significant as *p≤ 0.05, **p≤ 0.01. 
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Figure 18. Experimental design for experiments of subcutaneous PDA tumors 
treated with checkpoint inhibitors and αCD40/chemotherapy. Further described in 
Materials and Methods. (G=gemcitabine; nP=nab-paclitaxel; q3d= antibody administered 
every 3 days). 
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Figure 19. Checkpoint inhibitors alone do not inhibit tumor growth or improve 
survival in a subcutaneous PDA model. Tumor growth (A) and survival (B) analyses of 
mice bearing subcutaneous PDA tumors treated as indicated (n=9-10 per cohort; results 
for control and αPD-1+αCTLA-4 cohorts representative of 3 independent experiments). 
Two-way ANOVA (A) and log-rank (B) p values indicated. See also figure 23. 
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Figure 20. Agonist αCD40 and chemotherapy induces changes in tumor infiltrating 
T cells in subcutaneous PDA tumors. Flow cytometric analysis of mice bearing 
subcutaneous PDA tumors treated as indicated (day 7-8 after αCD40 treatment; 
G=gemcitabine; nP=nab-paclitaxel). (A) CD8+ T cells make up an increased percent of 
cells in the tumor after treatment. (B) Fewer CD8+ T cells co-express the exhaustion 
markers PD-1 and Lag-3 after αCD40/chemotherapy. More intratumoral CD8+ (C) and 
CD4+ (D) T cells are proliferating after αCD40/chemotherapy.  *p≤ 0.05, **p≤ 0.01. 
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Figure 21. Vaccination with αCD40 and chemotherapy potentiates the efficacy of 
αPD-1 and αCTLA-4 mAbs. Tumor growth (A) and survival (B) analyses of mice 
bearing subcutaneous PDA tumors treated as indicated (n=9-10 per cohort; findings 
representative of 3 independent experiments). Two-way ANOVA (A): p≤0.0001. Post 
hoc test p values indicated where significant as *p≤ 0.05, ***p≤ 0.001, ****p≤ 0.0001. 
Log-rank (B) p value indicated. See also figure 23. 
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Figure 22. Therapeutic combination of αCD40/chemotherapy with one or more 
checkpoint inhibitors leads to rejection of significant proportion of tumors. 
Percentage of mice bearing subcutaneous PDA tumors treated with indicated regimens 
that rejected their tumors and survived tumor-free long-term (median follow-up of 42 
days, range 23 to 146 days). Data compiled from 5 independent experiments. 
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Figure 23. Tumor growth curves of individual mice with subcutaneous PDA treated 
as indicated. Mice bearing subcutaneous PDA tumors, treated as described in Figures 19 
and 21 were assessed for tumor growth. Each graph represents all mice treated with 
indicated regimen; each line represents an individual mouse. 
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Figure 24. Tumor rejection and improved survival with vaccine and checkpoint 
inhibitor treatment is T cell dependent. Tumor growth (A) and survival (B) analyses of 
mice bearing subcutaneous PDA tumors treated as indicated (n=9-10 per cohort; 
G=gemcitabine; nP=nab-paclitaxel; TCD=CD4/CD8 depletion). Two-way ANOVA (A) 
and log-rank (B) p values indicated.  
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Figure 25. Immunotherapy improves CD8:Treg ratio and decreases intratumoral 
Treg percentage. Flow cytometric analysis of subcutaneous PDA tumors treated as 
indicated (day 18 after tumor injection, day 7 after αCD40 treatment; P=αPD-1; 
C=αCTLA-4). One way ANOVA: CD8:Treg Ratio (A), p=0.0005; %Tregs of CD4+ T 
cells (B), p=0.0004. Post hoc test p values indicated where significant as *p≤ 0.05,  
**p≤ 0.01, ***p≤ 0.001. 
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Figure 26. Majority of mice that rejected first tumor after immunotherapy reject 
tumor rechallenge with no further treatment. (A) Experimental design for 1st tumor 
rechallenge experiments. (B) Table quantifies fraction and percentage of mice that 
rejected tumor rechallenge in mice that had rejected the initial tumor implantation and 
were tumor-free for at least 43 days. Data compiled from 3 independent experiments. 
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Figure 27. The rejection of tumor rechallenges is CD8 T cell dependent. (A) 
Experimental design for 2nd tumor rechallenge experiment. The 2nd rechallenge occurred 
on day 31-49 after first rechallenge. (B) Table quantifies fraction and percentage of mice 
that rejected 2nd tumor rechallenge in mice that had rejected a 1st tumor rechallenge. Host 
mice in this experiment were either treated with αCD8 (n=11) or isotype (Iso; n=6) 
antibodies. Survival analysis of mice after 2nd rechallenge with or without CD8 depletion 
is shown (A). Log-rank p value is indicated (A). Data compiled from 2 independent 
experiments. 
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Figure 28. CD40 mAb but not chemotherapy alone potentiates tumor rejection by 
checkpoint inhibitors. Tumor growth (A) and survival (B) analyses of mice bearing 
subcutaneous PDA tumors treated as indicated (n=10 per cohort; G=gemcitabine; 
nP=nab-paclitaxel; same dose and schedule as Figure 18). Two-way ANOVA (A): 
p=0.272; log-rank (B): p<0.01. 
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Figure 29. The combination of αCD40/chemotherapy and checkpoint blockade 
improves survival in the KPC model of PDA. (A) Experimental design for randomized, 
controlled study in tumor-bearing KPC mice, treated with αCD40/chemotherapy and 
αPD-1, as described in Materials and Methods. (G=gemcitabine; nP=nab-paclitaxel; q3d= 
antibody administered every 3 days) (B) Overall survival analysis of tumor-bearing KPC 
mice treated as indicated (n=6-8 per cohort). αPD-1 alone vs. isotype alone p=0.39; 
CD40/G/nP vs. isotype alone p=0.76; CD40/G/nP + αPD-1 vs. isotype alone p=0.015. 
(C) Median overall survival of tumor-bearing KPC mice treated as indicated. 
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Treatment 
Cohort 
Days 
post 
CD40 
Clinical Signs Pathology 
CD40+G+nP 
+ CTLA-4 
3 Found dead  
CD40+G+nP 
+ CTLA-4 
3 Found dead  
CD40+G+nP 
+ CTLA-4 
3 Generally depressed and 
hunched; 1 day later 
developed vestibular 
signs (rolling, unable to 
stand); died 2 days later 
Intralesional bacterial cocci seen. Bilateral 
suppurative otitis externa and  media, mild 
focally extensive suppurative encephalitis 
and meningitis, and severe multifocal to 
focally extensive necrosuppurative 
sialoadenitis, cellulitis and myositis. 
CD40+G+nP 
+ CTLA-4 
4 Found dead  
CD40+G+nP 
+ PD-1 
4 Generally depressed, 
vestibular signs; died 1 
day later 
 
CD40+G+nP 
+ PD-1 
4 Generally depressed, 
vestibular signs; 
euthanized 3 days later 
Pseudomonas aeruginosa grown from inner 
ear. Marked, bilateral inflammatory 
exudate filling the external and middle 
canals and the nasolacrimal duct 
unilaterally. Unilaterally, at the base of the 
ear, there is focal necrotizing vasculitis with 
abundant neutrophils and fibrosis. The 
meninges are extensively and moderately 
expanded by neutrophils. Unilaterally the 
bulbar conjunctiva is infiltrated by 
abundant neutrophils. 
CD40+G+nP 
+ PD-1 
7 Mild vestibular signs; 
recovered and survived 
long term 
 
CD40+G+nP 
+ PD-1         
+ CTLA-4 
3 Generally depressed; 
died 3 days later 
 
Figure 30. Non-tumor related events and deaths in tumor bearing C57BL/6 mice 
after immunotherapy.C57BL/6 mice bearing subcutaneous tumors were treated as 
indicated. Mice bearing small tumors were occasionally found dead or ill; the 
presentation included clinical depression, hunching, poor appetite, and vestibular signs 
characterized by abnormalities of gait or posture and rolling behavior. For two moribund 
mice in which an extensive pathological characterization was performed, we diagnosed 
neutrophilic inflammation in the central nervous system (CNS). Evidence for bacterial 
infection was noted in both mice (Pseudomonas aeruginosa in one mouse; bacterial 
cocci, not otherwise specified, in the other). 
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CHAPTER 4 – T cell infiltration into spontaneous pancreatic tumors after induction of 
antitumor T cell response outside pancreatic microenvironment  
 
*The majority of the results described in this chapter are in a manuscript currently 
undergoing revisions at Gastroenterology: Beatty, G.L., Winograd, R., Evans, R.A., 
Long, K.B., Luque, S.L., Lee, J.W., Gladney, W.L., Guirnalda, P.D., and Vonderheide, 
R.H. Productive T cell immunity against pancreatic carcinoma in mice is regulated by 
Ly6Clow F4/80+ extratumoral macrophages 
 
INTRODUCTION 
In order to understand the mechanism of resistance of PDA to checkpoint inhibitor 
therapy I studied two mouse models, the genetically engineered KPC spontaneous tumor 
model, and subcutaneously implanted KPC derived PDA cell lines. Phenotypically, both 
models exhibited comparable high expression of the inhibitory PD-1 and PD-L1 axis on 
tumor associated T cells and APCs, respectively. Likewise, both models recapitulated the 
clinical resistance to single agent checkpoint inhibitor therapy seen to date in treated 
PDA patients (Brahmer et al., 2012; Le et al., 2013; Royal et al., 2010). And while in 
both models the addition of a vaccine to induce an antitumor T cell response potentiated 
the efficacy of checkpoint inhibitors, the types of responses observed in the two models 
were markedly different. In the subcutaneous PDA model large proportions of tumor 
bearing mice treated with vaccine and checkpoint inhibitors completely rejected their 
tumors and developed immune memory strong enough to reject subsequent tumor 
rechallenges. However, in the KPC model, while the combination of 
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αCD40/chemotherapy and αPD-1 was able to significantly improve overall survival, I 
observed no long term survivors or rejection of tumors. 
  The KPC model (as well as related Kras p16Ink4A model), has been widely 
adopted as the new murine standard for studying pancreatic cancer as it recapitulates the 
salient molecular, histopathologic, and clinical features of the human disease. As a 
preclinical model, the KPC GEMM has proved effective, as several agents shown to have 
antitumor efficacy in KPC mice have been tested in patients to similar results (Beatty et 
al., 2011; 2013; Provenzano et al., 2012). It is worth noting, however, that despite 
numerous studies of therapeutic interventions there is no published report of complete 
tumor rejection in a KPC tumor bearing mouse. The difference in the responses I 
observed between the KPC and subcutaneous models could be due to differences between 
the host mice, or to immunologic differences between the tumors that arise stochastically 
in the pancreas and the bolus of malignant cells implanted under the skin. 
 In order to determine whether the difference in responses is due to the host, I 
worked with Dr. Beatty, at the time a postdoctoral fellow in the lab of Dr. Vonderheide, 
who established a two tumor model by implanting a PDA cell line under the skin of KPC 
mice bearing pancreatic tumors. By treating these two tumor mice we could determine 
whether KPC resistance to immune therapy is due to systemic host immune deficiencies 
or instead due to local factors that abrogate responses that are successful against PDA 
tumors when located subcutaneously.  
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RESULTS 
αCD40 and chemotherapy can reject subcutaneous PDA tumors in a T cell 
dependent manner 
In a previously published study using the KPC model Dr. Vonderheide demonstrated that 
the combination of αCD40 and gemcitabine regressed tumors, but did so in a T cell 
independent manner (Beatty et al., 2011). No T cell response was seen in histologic 
analyses of these KPC tumors, and the regressions were shown to depend on the 
reprogramming of TAMs. The combination of αCD40 and gemcitabine as a vaccine has 
previously been reported, and in Chapter 3 I used the combination of gemcitabine, nab-
paclitaxel, and αCD40 above to induce T cell responses to subcutaneous tumors (Nowak 
et al., 2003). To determine whether this lack of a T cell response was specific to the KPC 
mice Dr. Beatty implanted a KPC derived cell line onto the flanks of normal littermates. 
In these studies we used littermate PC mice as hosts (as described in Materials and 
Methods). The previously published αCD40/gemcitabine KPC studies were done in KPC 
mice not backcrossed onto the C57BL/6 background (Beatty et al., 2011). In order to 
compare the results in the subcutaneous tumor studies described here to those previously 
published, we chose to adhere to mice with this mixed genetic background for these 
studies. We used a PDA cell line derived from a non-backcrossed KPC mouse and 
implanted the tumors onto KPC littermates of the same mixed background. Mice with 
subcutaneous PDA tumors were treated and monitored for tumor growth. Tumor 
regression was observed in a large proportion of mice treated with the combination of 
αCD40 and gemcitabine, however, depletion of CD4+ or CD8+ T cells abolished the this 
treatment effect (Figure 31). Histologic analysis of tumors from treated mice indicated 
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that a robust T cell infiltrate followed treatment, a finding distinct from what was found 
in the tumors of KPC mice treated the same way (Figure 32) (Beatty et al., 2011). These 
data indicate that αCD40 /gemcitabine induces a T cell dependent regression of 
subcutaneous PDA tumors, while this same treatment regimen does not induce a T cell 
response in KPC tumor bearing mice (Beatty et al., 2011). 
 
Pancreatic tumor bearing KPC mice are capable of mounting a T cell response 
against subcutaneous PDA tumors 
The differences between the immune effects of vaccination using chemotherapy and 
αCD40 in the two PDA models could be due to systemic immunological differences 
between KPC mice and control mice with implanted tumors. In order to determine 
whether KPC mice are systemically incapable of mounting a T cell response against a 
PDA tumor, we implanted the same PDA cell line subcutaneously in KPC mice bearing 
ultrasound diagnosed pancreatic tumors (Figure 33). After 12 days of growth, the KPC 
mice bearing two tumors were treated with the same dose and schedule of gemcitabine 
and αCD40 and monitored for tumor growth (Figure 33). In the absence of treatment 
implanted PDA tumor cell lines grew progressively in the KPC mice (Figure 34). Upon 
treatment with αCD40/gemcitabine, however, the subcutaneous tumors in KPC mice 
regressed (Figure 34). Histological analysis of these subcutaneous tumors revealed a 
strong T cell infiltrate in treated tumors (Figure 35A). The regressing tumors were 
marked by a statistically significant increase in both CD4+ and CD8+ T cells, while Tregs 
were unchanged (Figure 35B). This finding demonstrates that pancreatic tumor bearing 
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KPC mice are not systemically immunosuppressed, as they are capable of mounting an 
antitumor T cell response when the tumor is outside the pancreatic microenvironment.  
 
Explanted pancreatic KPC tumors remain susceptible to antitumor T cells induced 
by αCD40/gemcitabine 
Various cellular populations in the KPC tumor microenvironment have been reported to 
inhibit antitumor T cell responses, including fibroblasts, macrophages, and MDSCs 
(Bayne et al., 2012; Feig et al., 2013; Zhu et al., 2014). I have previously shown that the 
microenvironment of subcutaneous KPC derived PDA tumors resembles autochthonous 
KPC pancreatic tumors in PD-L1 expression and in the infiltration of suppressive 
leukocytes such as TAMs (Figures 3,4,7,11-13) (Bayne et al., 2012). It is nevertheless 
possible, and even likely, that certain facets of the KPC tumor microenvironment are not 
completely recapitulated in the cell line derived subcutaneous tumors. In order to test this 
hypothesis, spontaneous tumors explanted from KPC mice were re-implanted 
subcutaneously onto the flanks of other KPC mice harboring ultrasound diagnosed 
pancreatic tumors (Figure 36). Explanted tumors grew readily under the skin of KPC 
mice; mice with two tumors were treated 13 days after implantation with 
αCD40/gemcitabine (Figure 36). Half of treated mice demonstrated regression of the 
explanted tumors, and treated mice demonstrated a greater influx of both CD4+ and CD8+ 
T cells compared to untreated controls, indicating that T cells can traffic into the 
desmoplastic stroma of pancreatic tumors if effectively activated (Figure 37).  
 Given the strong T cell infiltration into the stromal explanted tumors, I examined 
the primary pancreatic tumors of these KPC mice bearing two tumors. Histologic 
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analyses of primary pancreatic tumors determined that “two tumor” mice treated with 
αCD40/gemcitabine had increased infiltration of T cells compared to untreated “two 
tumor” controls (Figure 38). Unlike the explanted tumors, the primary tumors showed a 
significant increase in the influx of CD4+ T cells while CD8+ T cells were not 
significantly increased in these tumors (Figure 38). This robust T cell infiltrate in primary 
pancreatic tumors was notable, and suggests that priming T cell responses outside the 
pancreatic TME may allow for the induction of antitumor T cells that can traffic into 
these tumors. These data indicate that the desmoplastic stroma of PDA is not the only 
barrier to T cell infiltration. Furthermore, the pancreatic location of the tumors seems to 
play a role in preventing an influx of T cells as the explanted tumors saw an increase in 
the CD8+ T cell infiltrate while the primary tumors did not. 
 
APCs in KPC peripancreatic lymph nodes express higher levels of PD-L1 than the 
same populations in inguinal lymph nodes draining subcutaneous PDA tumors 
One immunologic distinction between tumors in the pancreas and under the skin is 
lymphatic drainage. KPC tumors arising in the pancreas are drained by peripancreatic 
lymph nodes (PPLN) which are often enlarged compared to normal during tumor 
outgrowth. As pancreatic tumors develop they often engulf the PPLNs; PPLNs are 
increasingly difficult to microdisect from the tumors as they grow, and this process is 
observable by histology (Figure 39A). Tumors implanted subcutaneously on the flanks of 
mice are drained by the inguinal lymph node which can be visibly enlarged during tumor 
growth and especially after immunotherapy. The draining lymph nodes (DLN) of 
implanted tumors, however, remain spatially separated from the sucbcutaneous tumors 
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throughout tumor development (Figure 39B). This anatomic reality dictates that any 
tumor secreted factors, or factors produced by immune or mesenchymal populations in 
the tumor microenvironment, can directly affect the immune populations in PPLNs 
whereas that would be less likely (although still possible) for the spatially separate DLN 
of subcutaneous PDA tumors. This may provide an explanation for the fact that 
αCD40/chemotherapy can induce a T cell response against subcutaneous tumors but not 
primary pancreatic lesions. 
 When I analyzed the immune populations of these lymph nodes the most striking 
distinction was in the expression of PD-L1 on the APC populations. While the DCs and 
macrophages of the inguinal lymph nodes draining subcutaneous tumors exhibited a 
bimodal PD-L1 expression, as is seen in normal lymphoid tissue, APCs in PPLNs 
uniformly expressed high PD-L1, just as these same populations do in KPC and 
subcutaneous tumors (Figures 40, 41, 4, and 13). There was a significant difference in the 
percent of PD-L1 positive DCs (Figure 40) and macrophages (Figure 41) between PPLNs 
and inguinal LNs draining subcutaneous tumors, suggesting that APCs in PPLNs may be 
less able to prime antitumor T cell responses.  
 
CONCLUSIONS AND DISCUSSION 
Evasion of the immune system is necessary for malignant cells to develop into clinically 
apparent tumors. This evasion can be mediated through tumor cell intrinsic or extrinsic 
mechanisms. The process of immunoediting is the tumor cell intrinsic loss of antigenicity 
(through loss of the antigen or the ability to present it on MHC class I) or the loss of 
immunogenicity by the acquisition of immunosuppressive properties such as 
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overexpression of inhibitor receptors such as PD-L1 (Schreiber et al., 2011). Tumor cell 
extrinsic mechanisms have increasingly become appreciated as regulators of immune 
evasion; the recruitment of immunosuppressive leukocytic and mesenchymal populations 
to the tumor microenvironment has been shown to orchestrate networks of interacting 
cellular populations acting to both promote tumorigenesis through proangiogenic and 
tissue remodeling properties as well as locally suppress antitumor immune responses 
(Gabrilovich et al., 2012). The end result of these processes can be the establishment of 
localized ‘immune privileged’ sites in the tumor microenvironment, mechanistically 
similar to the intrinsic immune privilege of certain anatomic sites (Mellor and Munn, 
2008). In PDA there is ample evidence that the desmoplastic stromal reaction acts to 
suppress immune responses; TAMs, MDSCs, Tregs, and fibroblasts have been shown to 
inhibit antitumor T cell responses in studies of murine and human PDA (Bayne et al., 
2012; Beatty et al., 2011; Clark et al., 2007; Feig et al., 2013; Hiraoka et al., 2006). In the 
studies reported here I use two PDA models, the KPC GEMM and a subcutaneous PDA 
cell line model, to interrogate the role of the tumor microenvironment as a barrier to T 
cell immunotherapy. I show that αCD40 and chemotherapy, used as an antitumor 
vaccine, can induce a T cell response against subcutaneous PDA tumors, while the same 
treatment does not drive a T cell response against spontaneous KPC tumors, as Dr. 
Vonderheide has previously published (Beatty et al., 2011). This phenotype is not due to 
systemic immune suppression in KPC mice; T cell responses against subcutaneous PDA 
tumors in KPC mice bearing pancreatic tumors were achieved. Furthermore, when 
explanted from the pancreas and implanted subcutaneously, desmoplastic KPC tumors 
are likewise susceptible to T cell infiltration upon vaccination. A striking difference in 
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the PD-L1 expression in the lymph nodes draining pancreatic and subcutaneous tumors 
may explain the distinct effects of vaccination in these two models. Lastly, induction of 
antitumor T cells against a subcutaneous lesion leads to a T cell infiltration into primary 
pancreatic tumors in KPC mice, suggesting the possibility that T cell immunotherapy 
may yet be achievable for patients with PDA. 
 There is little evidence that PDA tumor cells undergo immunoediting in the 
classical sense. The presence of immunosuppressive MDSCs and Tregs at the PanIN 
stages suggests that these cells do not encounter the selective pressure of effector T cells 
(which are in fact rare, even in preneopalstic lesions) and hence are not required to lose 
antigenicity to grow out (Clark et al., 2007; Hiraoka et al., 2006). Analysis of 8 distinct 
early passage KPC derived PDA cell lines also indicates that while MHC class I is not 
highly expressed on these cells at baseline, it is readily upregulated in the presence of 
IFN-γ, indicating that the genetic locus and the regulation of MHC class I is intact in 
these cells (Figure 42).  Furthermore, PD-L1 expression on tumor cells themselves is 
moderate in vivo, and is not affected by IFN-γ in vivo despite the fact that it is readily 
upregulated on pancreatic tumor cells in vitro in response to IFN-γ (Figures 3, 16, and 
14). This indicates that despite having the capability of upregulating PD-L1 in the setting 
of immune pressure (a function of normal epithelial and endothelial tissues), there does 
not seem to be immune pressure on the pancreatic tumor cells in vivo (Keir et al., 2008). 
Implantation of subcutaneous PDA cell lines in KPC mice bearing pancreatic tumors led 
to normal tumor outgrowth, suggesting that there is no strong systemic antitumor T cell 
response that has developed in these KPC mice (Figure 34). I demonstrate that these 
subcutaneous tumors are susceptible to T cell mediated clearance, further indication of 
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their antigenicity. These data suggest that pancreatic tumor cells are not subject to 
immune mediated selective pressure directly, lending more credence to the notion that 
these tumors develop immune privileged sites. 
 As these tumors are antigenic and maintain MHC class I expression, it seems 
likely that the desmoplastic microenvironment mediates local immunosuppression. When 
we explanted pancreatic tumors and implanted them subcutaneously, however, we found 
that T cell responses could now be induced against these tumors with our vaccine (Figure 
37). Even more striking was the infiltration of T cells into the primary pancreatic tumors 
of these KPC mice bearing the subcutaneous explants after treatment (Figure 38). These 
data suggest that the inability to drive T cell responses against pancreatic tumors is not 
solely due to intra-pancreatic immune privilege. The fact that PPLNs are often engulfed 
by pancreatic tumors (Figure 39), and the remarkable upregulation of PD-L1 on APCs in 
these lymph nodes compared to the corresponding populations in lymph nodes draining 
subcutaneous tumors, suggests that disruption of normal immune function of lymph 
nodes plays a role in PDA’s resistance to immune therapy (Figures 40 and 41) (Mellor 
and Munn, 2008).  
 In summary, I have demonstrated that PDA tumor cells maintain the ability to 
express and regulate MHC class I, and that they are antigenic, as these tumors can be 
rejected in a T cell dependent manner after vaccination with αCD40 and gemcitabine. 
This same treatment does not induce T cell responses against pancreatic tumors in KPC 
mice, but these mice are not systemically immunosuppressed as subcutaneous PDA 
tumors can be rejected in a “two tumor” setting. The desmoplastic stroma of KPC tumors 
is not the only factor preventing T cell antitumor immunity as explanted pancreatic 
88 
tumors become susceptible to the vaccine when implanted under the skin. Dysfunction of 
PPLNs may contribute to the inability to induce T cells against pancreatic tumors. Lastly, 
I demonstrated that T cell trafficking into pancreatic tumors can be achieved when T cells 
can first be induced against a subcutaneous PDA tumor, offering hope for 
immunotherapeutic approaches in PDA patients. 
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Figure 31. αCD40 and gemcitabine regress subcutaneous PDA tumors in a T cell 
dependent manner. Normal littermates were implanted subcutaneously on day 0 with a 
KPC-derived tumor cell line. On day 13, mice were treated with gemcitabine or PBS 
followed 48 hours later by intraperitoneal injection of αCD40 (FGK45) or control IgG2a 
with cohorts of mice also receiving depleting antibodies for CD4 (GK1.5) and CD8 
(2.43) (as described further in Material and Methods). Waterfall plot of tumor response 
for each animal (n > 6 per group) determined by change in tumor volume measured 14 
days after treatment. Fisher's exact test: Gemcitabine/FGK45 vs 
Gemcitabine/FGK45/GK1.5, p = 0.001; Gemcitabine/FGK45 vs 
Gemcitabine/FGK45/2.43, p = 0.015. 
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Figure 32. T cells infiltrate subcutaneous PDA tumors after αCD40/chemotherapy 
treatment. Representative images from mice bearing subcutaneous tumors treated as 
indicated. Hematoxylin & eosin (H&E) staining and immunohistochemistry for CD3, 
CD4, and CD8 expressing cells. Scale bars: 50 μm.  
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Figure 33. Experimental design for ‘two-tumor’ model using PDA cell line. KPC 
mice diagnosed with pancreatic tumors by ultrasonography were implanted with a KPC 
derived PDA cell line. 12 days later mice were treated with gemcitabine, followed by 
αCD40 (FGK45) two days later. 
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Figure 34. Subcutaneous tumors in KPC mice bearing pancreatic tumors regress 
after αCD40/gemcitabine treatment. Tumor growth curves of subcutaneously 
implanted tumors in mice (n = 3 per group) treated with control  versus gemcitabine 
(Gem) plus αCD40 (FGK45). 
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Figure 35. T cell infiltration into subcutaneous PDA tumor in pancreatic tumor 
bearing KPC mice after αCD40/gemcitabine. (A) Representative images showing 
H&E staining and immunohistochemistry for CD4, CD8, and Foxp3 expressing cells in 
subcutaneously growing tumors from mice 14 days after the indicated treatment. Scale 
bars: 100 μm. (B) Quantification (courtesy of Dr. Beatty, as are quantification in Figures 
37, 38) of cellular infiltrates into tumors detected by immunohistochemistry 14 days after 
the indicated treatment (n = 4 per group). Student's t test: CD4, p = 0.002; CD8, p = 
0.043; Foxp3, p = 0.482. 
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Figure 36. Experimental design for “two tumor” model using explanted KPC tumor. 
On day 0, explanted PDA tissue was re-implanted subcutaneously into KPC mice with 
ultrasound confirmed spontaneous pancreatic tumors. Mice were treated on day 13 with 
gemcitabine or PBS followed 48 hours later by intraperitoneal injection of αCD40 
(FGK45) or control IgG2a. 
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Figure 37. Robust T cell infiltration into explanted KPC tumors after treatment 
with αCD40/gemcitabine. (A) Representative images showing H&E staining and 
immunohistochemistry for CD4, CD8, and Foxp3 expressing cells in subcutaneously 
growing explanted KPC tumors from mice 14 days after the indicated treatment. Scale 
bars: 50μm. (B) Quantification of cellular infiltrates into responding explant tumors 
detected by immunohistochemistry 14 days after the indicated treatment (n = 4 per 
group). Student's t test: *p< 0.05, **p<0.01, ***p<0.005. 
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Figure 38. T cell infiltration in primary pancreatic KPC tumors in mice bearing two 
tumors after αCD40/gemcitabine. (A) Representative images showing H&E staining 
and immunohistochemistry for CD4, CD8, and Foxp3 expressing cells in primary 
pancreatic KPC tumors in mice also bearing an explanted KPC tumor. Scale bars: 50μm. 
(B) Quantification of cellular infiltrates into spontaneous primary pancreatic tumors 
detected by immunohistochemistry 14 days after the indicated treatment (n = 4 per 
group). Student's t test: *p< 0.05, **p<0.01. 
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Figure 39. Peripancreatic lymph nodes are often engulfed by pancreatic tumors in 
KPC mice. (A) H&E image of involved peripancreatic lymph node surrounded by 
pancreatic tumor. 40x magnification. (B) Left- H&E image of subcutaneous PDA tumor; 
Right- H&E image of inguinal lymph node draining subcutaneous PDA tumor. 40x 
magnification. 
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Figure 40. Significantly more DCs in peripancreatic LNs express PD-L1 compared 
to DCs in inguinal LNs draining subcutaneous tumors. Representative histogram of 
PD-L1 expression on DCs (gated as above) from (A) KPC peripancreatic lymph nodes 
(PPLN; n=14) or (B) inguinal lymph node draining implanted subcutaneous tumor 
(n=23). (C) Quantification of %DCs PD-L1+. Student's t test: ****p<0.0001. 
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Figure 41. Significantly more macrophages in peripancreatic LNs express PD-L1 
compared to macrophages in inguinal LNs draining subcutaneous tumors. 
Representative histogram of PD-L1 expression on Macs (gated as above) from (A) KPC 
peripancreatic lymph nodes (n=14) or (B) inguinal lymph node draining implanted 
subcutaneous tumor (n-23). (C) Quantification of %Macs PD-L1+. Student's t test: 
****p<0.0001. 
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Figure 42. MHC I (H-2Kb) expression on PDA cell lines can be upregulated by IFN-
γ in vitro. (A) Representative histogram of a KPC-derived PDA cell line interrogated for 
MHC I expression in vitro with or without IFN-γ in the culture, and (B) quantification of 
8 distinct KPC-derived PDA cell lines interrogated for MHC I expression in vitro with or 
without IFN-γ. 
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CHAPTER 5 – Discussion and Future Directions 
 
The remarkable clinical successes of mAbs blocking the negative immune checkpoint 
proteins PD-1/PD-L1 and CTLA-4 has prompted investigations to replicate these 
responses in other malignancies. Paramount to expanding the populations that can benefit 
from these therapies is an improved understanding of resistance mechanisms. Some 
tumor types appear to be completely resistant; for example, patients with pancreatic 
cancer have been treated with these agents but no responses have been reported (Brahmer 
et al., 2012; Le et al., 2013; Royal et al., 2010). In this thesis project I studied a genetic 
model of pancreatic carcinoma which recapitulates the salient molecular, histopathologic, 
and clinical features of the human disease in order to understand the resistance of this 
tumor to checkpoint inhibitors and interrogate approaches to overcome this resistance. In 
Chapter 3 I describe the expression of PD-1 and its ligand PD-L1 in the KPC model of 
PDA and confirm the relevance of our work by analysis of human pancreatic tumors. I 
developed a subcutaneous model of PDA which is resistant to single agent (and, in fact, 
combinatorial) checkpoint inhibitors mimicking the clinical results to date. I 
hypothesized that the dearth of effector T cells in pancreatic tumors precluded clinical 
efficacy of mAbs blocking negative checkpoints, and that induction of a T cell response 
would overcome resistance in this model. Using an agonist αCD40 mAb, combined with 
chemotherapy to induce immunogenic cell death, I induced a T cell response against 
PDA tumors and potentiated antitumor effects of checkpoint inhibition; large proportions 
of tumors were rejected in a T cell dependent manner. Combination treatment also 
improved survival of KPC mice, highlighting the clinical relevance of my work. In 
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Chapter 4 I interrogated the immunologic differences between the subcutaneous and 
pancreatic PDA tumors models. Working with Dr. Beatty, we demonstrated that although 
the desmoplastic tumor microenvironment of KPC tumors plays a role in inhibiting 
antitumor T cell responses, explanting pancreatic tumors and implanting them 
subcutaneously allows for the induction of antitumor T cells. These data suggest that 
lymph nodes draining pancreatic tumors may preclude proper T cell activation; I found 
that significantly more APCs in the PPLNs express PD-L1 than APCs in lymph nodes 
draining subcutaneous tumors. Importantly, the induction of an antitumor T cell response 
in a “two tumor” model led to a T cell infiltrate in the primary pancreatic tumors, 
providing insight on immunotherapeutic approaches for patients with PDA. In the pages 
below I will discuss the strengths and limitations of the data presented here, analyze them 
within their context in the literature, and offer thoughts on future directions for these 
projects; some of the finer points of the data are analyzed in more detail in the concluding 
sections of Chapters 3 and 4 above. 
 
Experimental mouse models of PDA 
Genetic mouse models have facilitated the study of the tumor microenvironment. Driven 
by the same oncogenes that initiate carcinogenesis in human malignancy, murine cancers 
in GEMMs replicate the tumorigenic processes of acquiring further genetic hits, and 
overcoming immune surveillance before becoming clinically apparent lesions. These 
processes, occurring stochastically over time in immune competent hosts lead to the 
development of lesions that differ greatly from the human transplanted tumors grown in 
nude mice which had long dominated oncologic investigations. The KPC GEMM used in 
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the Vonderheide lab, as well as many others, recapitulates human PDA in the 
development of desmoplastic tumors harboring robust immune and mesenchymal 
infiltrates which affect tumor initiation and development. Crucially, successful preclinical 
studies in this model have been translated to the clinic where early results indicate a high 
degree of fidelity in the types of responses achieved in patients (Beatty et al., 2011; 
Provenzano et al., 2012; Rhim et al., 2014). 
The great strengths of the KPC model are unfortunately counteracted by the slow 
breeding process and the stochasticity of the model which necessitates regular palpation 
and ultrasound monitoring in order to diagnose nascent tumors. The pancreatic 
transcription factor Pdx-1 comes on at embryonic day 9.5 in these mice, meaning that 
oncogenes are activated in utero, which differs from human PDA, and could potentially 
affect the immune response to these tumors (Hingorani et al., 2003). These factors 
preclude large scale studies and the repeating of experiments as enrollment for any study 
can take months. In the studies described in this thesis, I used the KPC model to identify 
the prominence of the PD-1/PD-L1 axis in pancreatic cancer. After determining that this 
pathway is overexpressed in the KPC model, I established a subcutaneous tumor model in 
immune competent mice which recapitulates this phenotype in order to greatly accelerate 
the pace and scope of my studies. As described above, the subcutaneous tumors that 
developed were able to form desmoplastic tumors with similar immune infiltrates to the 
KPC tumors, and, fundamental to my studies, established subcutaneous PDA tumors 
were resistant to therapeutic mAbs against PD-1 and CTLA-4. This resistance 
recapitulated the clinical results to date of single agent checkpoint inhibitors in pancreatic 
cancer, and distinguishes this subcutaneous model from other murine studies which found 
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significant tumor rejection upon single agent treatment with αPD-1 or αCTLA-4 (Sandin 
et al., 2014; Soares et al., 2014). After determining that a vaccine can potentiate 
checkpoint inhibitors in this model, I returned to the KPC model to validate these 
findings. Despite an almost doubling of overall survival, a significant finding comparable 
to other successful studies in KPC mice, I did not observe complete tumor eradication in 
any KPC mice (Olive et al., 2009). While there is no published report of a tumor bearing 
KPC mouse cured of its disease, the gulf between the responses in the two models 
warrants further investigation. The differences in the lymphatic drainage of the two tumor 
systems, and the marked increase in PD-L1 expression on APCs of PPLNs draining KPC 
tumors suggests that this treatment may fail to overcome the immune privileged 
microenvironment established by KPC tumors. A slight but statistically significant 
increase in the percentage of DCs in subcutaneous PDA tumors vs KPC tumors might 
also facilitate the induction of T cell responses in that model (Figure 7). Further studies to 
understand these differences and elucidate the mechanisms which govern PD-L1 
expression in the KPC microenvironment would potentially provide additional targets 
and improve rational design of therapeutic interventions in this disease.  
 
IFN-γ and adaptive resistance  
Although PD-L1 expression remains responsive to IFN-γ in PDA cell lines in vitro, I 
found that the regulation of PD-L1 expression in vivo in the PDA tumor 
microenvironment does not require IFN-γ. Genetic loss of IFN-γ or depletion of T cells 
did not affect tumor cell PD-L1, and there was only minimally decreased PD-L1 on 
tumor APCs in IFN-γ-/- mice. These findings differ from the prevailing notions of PD-L1 
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expression in cancer. Immunohistochemical studies of various human malignancies 
(melanoma, NSCLC, RCC, HNSCC, and bladder cancer) have all demonstrated that 
tumor associated PD-L1 expression often co-localizes with lymphocytic immune 
infiltrates, specifically CD8+ TILs (Lyford-Pike et al., 2013; Powles et al., 2014; Taube et 
al., 2012; 2014; Velcheti et al., 2013). These data suggest that in many malignancies the 
upregulation of PD-L1 (on tumor cells or tumor associated immune cells) functions to 
locally dampen antitumor T cell responses, a concept termed adaptive immune resistance 
(Taube et al., 2012; Tumeh et al., 2014). Mechanistically, this upregulation is thought to 
occur upon exposure to IFN-γ secreted by activated infiltrating CD8+ T cells, a pathway 
that regulates PD-L1 expression on normal epithelial tissues (Keir et al., 2008). In a 
recent study of murine melanoma, tumor cell PD-L1 expression was demonstrated to be 
dependent on CD8+ T cells and the secretion of IFN-γ, validating this hypothesis 
(Spranger et al., 2013). In contrast, both of the PDA mouse models I studied expressed 
high PD-L1 in the tumor microenvironment despite harboring minimal intratumoral T 
cells, indicating that despite the prevalence of this pathway in the PDA 
microenvironment, PD-L1expression does not appear to be an adaptive response to 
immune pressure. These findings in the KPC model are corroborated by the observations 
in human PDA, in which there was no spatial correlation between tumor PD-L1 
expression and the presence of intratumoral CD8+ T cells. Tumor PD-L1 expression has 
been reported to be regulated by oncogenes such as EGFR,  but oncogenic Kras (at least 
in lung carcinoma) does not induce PD-L1 expression (Akbay et al., 2013), suggesting 
that the regulation of PD-L1 in PDA may differ from other solid malignancies. As such, 
it is important to note that intratumoral PD-L1 does not necessarily serve as a biomarker 
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of an ongoing antitumor immune response. Investigations in other tumor types that 
harbor few TILs would illuminate whether PD-L1 upregulation in the absence of CD8+ T 
cells and IFN-γ is specific to PDA or whether it is a common feature of immune 
privileged tumors. 
 
Understanding resistance to αPD-1 and αCTLA-4 mAbs 
Recently published studies have determined that pretreatment intratumoral PD-L1 
expression is in fact predictive of patient responses to αPD-1/αPD-L1 (Herbst et al., 
2014; Powles et al., 2014; Tumeh et al., 2014; Taube et al., 2014). However, unlike 
targeted therapies like trastuzumab or vemurafenib, the presence of PD-L1 in the tumor 
does not seem to be important for its presence, per se, but rather for the fact that it is 
indicative of an ongoing antitumor T cell response which is being suppressed by PD-L1 
expression. The presence of TILs or CD8+ T cells, or the intratumoral expression of IFN-
γ or CTLA-4 in pretreatment biopsies also independently predict response to αPD-1 or 
αPD-L1 in these same studies (Herbst et al., 2014; Taube et al., 2012; Kvistborg et al., 
2014). Furthermore, in bladder and lung cancers tumor cell PD-L1 does not correlate 
with response, whereas PD-L1 expression on infiltrating immune cells does correlate 
with response to αPD-L1 (Herbst et al., 2014; Powles et al., 2014). If PD-L1 expression 
were, in fact, primarily important in preventing the targeting of malignant cells by PD-1+ 
CD8+ T cells then tumor cell PD-L1 should be the metric which correlates with response, 
not the PD-L1 on other cells in the TME. Two papers offer first in human evidence of the 
T cell effects of αPD-1 and αCTLA-4; patients treated with ipilimumab had increased 
levels of antigen specific antitumor CD8+ T cells, and responders to pembrolizumab 
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showed increased intratumoral CD8+ T cells compared to nonresponders (Kvistborg et 
al., 2014; Tumeh et al., 2014). In the context of these data, the lack of response to 
checkpoint inhibitors in PDA, despite expression of PD-1 and PD-L1 in the TME, makes 
sense, as few effector T cells are present in these tumors at baseline, indicating the lack of 
a response to be rescued (Figure 43). 
While large subsets of some malignancies present with robust T cell infiltrates or 
have inflammatory gene signatures, PDA does not commonly present with a robust tumor 
infiltration of CD8+ T cells (Bernstorff et al., 2001; De Monte et al., 2011; Fukunaga et 
al., 2004; Gajewski et al., 2010; Galon et al., 2006; Hiraoka et al., 2006; Zhang et al., 
2003). PDA is associated with multiple immunosuppressive populations starting at the 
premalignant stage, likely preventing effector T cells from sculpting these tumors, as 
evidenced by the retention of MHC class I regulation in KPC derived cell lines (Bayne et 
al., 2012; Beatty et al., 2011; Clark et al., 2007; 2008; Zhang et al., 2014). TILs in PDA 
tumors express more PD-1 than T cells in mice chronically infected with LCMV (in 
which αPD-1 can rescue T cell function (Barber et al., 2006)); yet αPD-1 treatment has 
no effect on tumor growth in PDA, suggesting that the TILs in PDA are not prevented 
from targeting the tumor simply by encountering negative checkpoint molecules (Figure 
43). These data suggest that unlike other malignancies, the PDA microenvironment may 
act as an immune privileged site, a paradigm which has implications for 
immunotherapeutic approaches (Vonderheide et al., 2013). I propose that response to 
αPD-1 and αCTLA-4 in these PDA models is unlikely, and that both the induction of 
antitumor T cells with a vaccine, and the blockade of negative immune checkpoints are 
necessary for successful immune therapy in these kinds of tumors. In fact, one clinical 
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study combined ipilimumab with a PDA cellular vaccine and an improvement in median 
overall survival (5.7 months vs. 3.6 months; p=0.072) was observed in comparison to 
patients treated with ipilimumab alone, supporting my findings in mice (Le et al., 2013). 
The observation that αCD40/chemotherapy converts PDA from a tumor that is 
fully refractory to checkpoint inhibition to one that is highly sensitive, is important in the 
context of prior efforts to extend the therapeutic range of αPD-1 and αCTLA-4. My goal 
was to use a murine model that reproduces the lack of clinical effect observed to date 
with αPD-1 and αCTLA-4 in PDA, in contrast to many tumor models that exhibit 
baseline levels of responsiveness to αCTLA-4, αPD-1, αPD-L1 or combinations of these 
agents.  For example, in models of colon carcinoma, melanoma, ovarian cancer, bladder 
cancer, and neuroblastoma, checkpoint inhibitor therapy alone inhibits tumor growth, 
improves survival, and occasionally mediates complete rejection (Curran et al., 2010; 
Duraiswamy et al., 2013; Leach et al., 1996; Mangsbo et al., 2010; Williams et al., 2013). 
In a recent study using the Panc02 subcutaneous PDA model, tumor rejection was 
observed in 50% of mice after treatment with αCTLA-4 (Sandin et al., 2014), a finding 
not representative of the clinical record of αCTLA-4  in patients with PDA (Le et al., 
2013; Royal et al., 2010) and possibly related to Panc02 being a carcinogen-induced and 
likely hypermutated tumor (whereas human PDA is not a hypermutated tumor (Jones et 
al., 2008)). In another study of the Panc02 model, αPD-1 treatment significantly slowed 
tumor growth and led to complete tumor rejection in 22% of mice (Soares et al., 2014). 
Previous work in these types of models demonstrates that T cell stimulatory therapies 
including vaccines, peritumoral poly(I:C), and intratumoral oncolytic virus can improve 
baseline effects of checkpoint blockade (Bald et al., 2014; Duraiswamy et al., 2013; 
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Zamarin et al., 2014; Zhou et al., 2010). In PDA, the stimulation of a T cell response 
using αCD40/chemotherapy is able to fundamentally transform a tumor that is refractory 
to checkpoint inhibition into a highly sensitive one, rather than only improving upon 
baseline activity of checkpoint mAb (Figure 43). I demonstrated that αCD40 rather than 
chemotherapy is crucial for potentiating the effects of checkpoint inhibitors in this PDA 
model; the role and sequencing of chemotherapy in potentiating or inhibiting 
immunotherapy will require significant further investigation. It is likely that alternate 
approaches to induce T cell responses, including the use of Toll like receptor (TLR) 
agonists such as CpG or polyI:C, among other vaccine approaches, would also synergize 
with αPD-1 or αCTLA-4 in PDA (Buhtoiarov et al., 2010; Cho and Celis, 2009; Davila et 
al., 2003; Scarlett et al., 2009).  
 
Summary and closing remarks 
With the clinical success of mAbs blocking negative immune checkpoints in 
malignancies ranging from melanoma to bladder cancer, efforts are underway to replicate 
these results in other tumor types. In patients with PDA these agents have failed to date, 
and I propose here that these results are indicative of an immune privileged tumor 
microenvironment which precludes antitumor T cells (Figure 43). Using two models of 
pancreatic cancer, I demonstrate that despite high expression of PD-L1 and PD-1 in 
pancreatic tumors, treatment with αPD-1 fails to slow tumor growth or improve survival. 
Unlike other tumors, where PD-L1 expression is indicative of an adaptive resistance to 
immune pressure, PD-L1 in PDA is not dependent on IFN-γ or CD8+ T cells, indicating 
that regulation of this pathway differs between tumor types. Using a vaccine approach, I 
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induced an antitumor T cell response which was significantly augmented with the 
addition of checkpoint inhibitors, leading to rejection of tumors in a large subset of mice. 
Significant survival improvement in KPC mice treated with vaccine and αPD-1 suggests 
this approach may prove effective in patients with PDA as this model has previously 
predicted clinical responses. These results may be more broadly applicable to non-
immunogenic malignancies, providing a template for expanding the reach of 
immunotherapeutic approaches. 
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Figure 43. Proposed model describing types of immune responses to cancer and 
implications for immunotherapy. 
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